data_1cw6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1cw6 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.752 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.611 ' HA3' ' CB ' ' A' ' 21' ' ' ALA . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.686 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.607 0.241 . . . . 0.0 110.651 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.555 HG13 ' H ' ' A' ' 18' ' ' TRP . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.457 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.555 ' H ' HG13 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.752 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.611 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.628 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.698 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.709 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 5' ' ' ASN . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 2.8 m-20 -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.709 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' TYR . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.698 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.572 0.225 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.496 HG13 ' O ' ' A' ' 6' ' ' GLY . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.471 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.527 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.563 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.821 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.412 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.821 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.521 ' CD1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.466 HG12 ' HD2' ' A' ' 3' ' ' TYR . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.596 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 CA--C 1.518 -0.257 0 CA-C-O 120.74 0.305 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.555 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.556 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.43 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.607 ' O ' HG21 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.607 HG21 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.415 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.552 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.544 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.544 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 42.9 m . . . . . 0 CA--C 1.513 -0.467 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.446 HG13 ' CD2' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.47 ' O ' ' N ' ' A' ' 22' ' ' PHE . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.419 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.504 ' O ' HG22 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.617 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.763 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.733 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.6 m120 -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' CG1' ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 6' ' ' GLY . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.763 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 p . . . . . 0 CA--C 1.521 -0.14 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.487 ' CG1' ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.446 ' CD2' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.47 ' CD1' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.412 ' C ' ' CD1' ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.728 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.724 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.487 ' CG2' ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.728 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.43 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.667 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.601 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.538 ' NE1' ' CG1' ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.404 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.467 ' CD1' HG22 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.467 HG22 ' CD1' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.437 ' CE1' ' O ' ' A' ' 23' ' ' SER . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.606 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.674 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.652 ' HA2' ' CZ ' ' A' ' 2' ' ' TYR . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.606 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.635 0.255 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.469 HG12 ' O ' ' A' ' 6' ' ' GLY . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.527 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' PHE . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.674 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.424 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 18' ' ' TRP . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.688 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.77 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.454 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.651 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.454 ' HB ' ' HB2' ' A' ' 3' ' ' TYR . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.688 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 79.8 p . . . . . 0 N--CA 1.454 -0.263 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.56 HG12 ' O ' ' A' ' 6' ' ' GLY . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.411 ' CD2' HG13 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.77 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.503 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.406 ' O ' ' CB ' ' A' ' 30' ' ' ALA . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.667 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.732 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.604 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 6' ' ' GLY . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.732 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.186 0 CA-C-O 120.695 0.283 . . . . 0.0 110.965 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.604 HG11 ' O ' ' A' ' 6' ' ' GLY . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.434 ' CD2' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.595 ' HB3' ' HH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.507 ' HB1' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.425 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.722 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.602 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.621 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.488 HG21 ' O ' ' A' ' 6' ' ' GLY . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t . . . . . 0 N--CA 1.455 -0.191 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 6' ' ' GLY . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.505 ' O ' ' N ' ' A' ' 22' ' ' PHE . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.413 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 18' ' ' TRP . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.687 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.411 HG21 ' CD1' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.425 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.687 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.848 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.636 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.401 ' O ' ' N ' ' A' ' 5' ' ' ASN . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.585 ' HA3' ' CB ' ' A' ' 21' ' ' ALA . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 6' ' ' GLY . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.848 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t . . . . . 0 CA--C 1.523 -0.085 0 CA-C-O 120.654 0.264 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.516 HG11 ' CD2' ' A' ' 18' ' ' TRP . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB3' ' OE1' ' A' ' 20' ' ' GLU . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.516 ' CD2' HG11 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.636 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.585 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.406 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 30' ' ' ALA . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.442 ' CE1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.417 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.697 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.516 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.697 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.424 -0.213 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.498 HG11 ' CD2' ' A' ' 18' ' ' TRP . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.539 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 0.8 OUTLIER -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.498 ' CD2' HG11 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.539 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.516 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.594 HG21 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.465 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.579 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.772 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.772 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.577 0.227 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.498 ' HB2' ' HH ' ' A' ' 2' ' ' TYR . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.443 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.718 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 6' ' ' GLY . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.718 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.575 HG11 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.497 ' CD2' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.501 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.625 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.462 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.404 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.448 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.445 ' HB2' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.796 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.657 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.42 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.796 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.549 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.403 ' CE1' HG21 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.833 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.438 HG12 ' HB3' ' A' ' 30' ' ' ALA . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.833 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.438 ' HB3' HG12 ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.68 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 88.4 p . . . . . 0 CA--C 1.519 -0.232 0 CA-C-O 120.653 0.263 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.68 HG11 ' O ' ' A' ' 6' ' ' GLY . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.435 ' CG ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.404 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.464 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.694 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.459 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.605 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.781 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.444 ' HD2' HG13 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.639 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG13 ' HD2' ' A' ' 3' ' ' TYR . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.781 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 6' ' ' GLY . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.411 ' CD2' HG11 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.521 ' O ' HG21 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.521 HG21 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' CG ' ' O ' ' A' ' 23' ' ' SER . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' TYR . . . . . 0.714 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' TYR . . . . . 0.493 ' HD2' HG11 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.636 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.493 HG11 ' HD2' ' A' ' 3' ' ' TYR . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.714 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 CA--C 1.521 -0.15 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.51 ' O ' ' N ' ' A' ' 22' ' ' PHE . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.823 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.526 ' HB1' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.752 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.611 ' HA3' ' CB ' ' A' ' 21' ' ' ALA . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.686 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -128.04 147.57 50.52 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.8 m -109.67 97.88 7.34 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.703 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 69.3 p -98.91 158.35 15.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.08 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 36.1 34.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.409 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p 74.04 47.0 0.16 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.424 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.557 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -161.92 127.19 1.68 Allowed Glycine 0 N--CA 1.452 -0.288 0 N-CA-C 111.466 -0.653 . . . . 0.0 111.466 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 57.0 m -88.47 126.6 35.32 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 121.476 0.655 . . . . 0.0 111.22 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -146.62 173.74 12.06 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.651 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.555 HG13 ' H ' ' A' ' 18' ' ' TRP . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.457 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.555 ' H ' HG13 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.752 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.611 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.628 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.628 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.87 -1.18 10.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -82.02 -35.23 29.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.85 0.357 . . . . 0.0 110.922 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -82.48 59.7 4.91 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.551 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.408 ' O ' ' N ' ' A' ' 35' ' ' GLY . . . -99.18 78.55 0.52 Allowed Glycine 0 CA--C 1.517 0.213 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.674 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 66.11 -61.12 0.29 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.408 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -148.48 -145.97 4.25 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.678 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER 55.64 80.77 0.13 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.75 0.309 . . . . 0.0 110.915 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.896 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.698 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.709 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.42 ' O ' ' N ' ' A' ' 5' ' ' ASN . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 2.8 m-20 -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.709 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' TYR . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.698 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -111.09 161.27 16.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.65 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 18.8 m -124.31 85.9 2.48 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.299 0.571 . . . . 0.0 109.831 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.766 ' O ' ' N ' ' A' ' 12' ' ' SER . 6.8 p -103.97 143.86 32.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.158 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 mmmm 22.55 -61.46 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 178.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.766 ' N ' ' O ' ' A' ' 10' ' ' THR . 59.1 p -81.82 3.49 25.76 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -177.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.626 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 114.9 -155.29 16.44 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.94 178.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.65 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 61.4 m -92.5 127.52 38.02 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.542 0.687 . . . . 0.0 111.52 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p -146.47 170.52 16.68 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.494 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.496 HG13 ' O ' ' A' ' 6' ' ' GLY . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.471 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.527 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.563 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.448 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.821 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.452 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.821 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.67 -21.05 66.1 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.452 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 21.8 t-20 -83.71 62.26 6.78 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 150.35 -21.94 1.08 Allowed Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.828 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -153.83 113.96 0.6 Allowed Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.534 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -150.78 102.38 2.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.112 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.96 35.32 3.85 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.207 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -77.61 129.67 35.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.837 0.351 . . . . 0.0 111.107 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 3.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.154 -0.927 . . . . 0.0 110.94 179.582 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.521 ' CD1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.466 HG12 ' HD2' ' A' ' 3' ' ' TYR . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.596 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -120.12 151.0 39.7 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.608 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.3 m -113.54 87.59 2.64 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.3 p -91.36 133.91 35.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.679 -178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.6 tttt 77.73 -84.27 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.44 22.68 0.54 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.5 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -152.98 147.05 16.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.163 -1.018 . . . . 0.0 112.885 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.608 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 53.6 m -92.31 128.29 38.11 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-O 121.364 0.602 . . . . 0.0 110.731 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m -145.99 152.51 39.5 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.683 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.555 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.556 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.43 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.607 ' O ' HG21 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.607 HG21 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.415 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -74.26 -18.35 60.74 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.4 t-20 -76.33 82.13 3.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.069 0.461 . . . . 0.0 110.794 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -177.66 -46.65 0.07 OUTLIER Glycine 0 C--N 1.331 0.271 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.28 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.64 4.48 34.64 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.005 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -89.8 -46.96 8.22 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.833 0.317 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 163.46 124.64 0.72 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.893 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 72.29 -155.83 0.09 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 120.48 0.181 . . . . 0.0 111.268 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.3 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.552 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.544 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.544 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -109.51 151.26 26.98 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.635 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -119.39 78.21 1.28 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.499 0.666 . . . . 0.0 109.758 179.869 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.584 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -94.14 135.42 35.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.508 -179.249 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 10' ' ' THR . 5.0 mmmt 83.21 -89.68 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.555 179.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 p -149.61 20.79 0.92 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.539 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.16 159.72 29.9 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.743 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.635 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 35.5 m -93.17 132.74 37.04 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.609 0.718 . . . . 0.0 110.926 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 42.9 m -111.27 -178.46 3.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.999 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.446 HG13 ' CD2' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.47 ' O ' ' N ' ' A' ' 22' ' ' PHE . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.419 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.504 ' O ' HG22 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.617 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.504 HG22 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -64.85 -15.36 61.76 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 33' ' ' GLY . 16.4 t30 -84.52 -36.56 22.11 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.935 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 48.8 97.86 0.01 OUTLIER Glycine 0 CA--C 1.519 0.341 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.061 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . 96.71 149.18 25.23 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.166 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -82.38 69.26 9.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.095 0.474 . . . . 0.0 110.21 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.8 -36.88 24.38 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.06 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 77.42 112.22 0.07 Allowed 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 120.67 0.272 . . . . 0.0 110.696 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.688 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.763 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.733 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.6 m120 -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' CG1' ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 6' ' ' GLY . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.763 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -120.44 151.25 39.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.4 m -127.21 92.07 3.45 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.517 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.5 p -96.17 118.25 32.37 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.665 -178.415 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 10' ' ' THR . 2.1 mmmp? 87.57 -85.38 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.505 179.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.0 p -150.49 31.89 0.65 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.478 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.416 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -159.89 143.91 9.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.002 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 62.0 m -97.59 139.55 33.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.573 0.702 . . . . 0.0 111.726 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 p -125.7 171.62 10.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.065 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.487 ' CG1' ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.446 ' CD2' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.47 ' CD1' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.47 HG23 ' CD1' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.472 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.412 ' C ' ' CD1' ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -67.04 -22.63 65.86 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.472 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.5 t30 -80.79 68.85 7.18 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.542 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.7 96.94 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.251 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.09 118.42 3.97 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.762 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -150.93 -46.86 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.841 0.353 . . . . 0.0 110.662 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 86.08 140.66 5.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.714 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -162.21 35.43 0.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.85 0.357 . . . . 0.0 110.549 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.2 m-90 . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.908 -179.983 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.728 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.724 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.487 ' CG2' ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.728 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.1 OUTLIER -139.7 127.15 21.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.3 OUTLIER -106.44 89.35 3.01 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.421 0.629 . . . . 0.0 110.004 179.139 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -96.89 -167.53 1.56 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.274 -179.164 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' N ' ' OG1' ' A' ' 10' ' ' THR . 0.0 OUTLIER -56.47 -21.22 24.19 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.454 -178.91 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 91.1 p -94.04 16.6 14.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.366 178.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 90.6 -155.94 24.4 Favored Glycine 0 C--N 1.333 0.403 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.729 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 45.7 m -90.86 131.1 36.7 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.43 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -150.21 110.94 4.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 -179.35 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.667 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.601 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.538 ' NE1' ' CG1' ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.404 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.467 ' CD1' HG22 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.467 HG22 ' CD1' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.437 ' CE1' ' O ' ' A' ' 23' ' ' SER . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -70.83 -29.96 66.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.6 t-20 -81.24 59.39 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.051 0.453 . . . . 0.0 110.767 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 72.48 0.57 Allowed Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.329 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.02 -37.99 0.14 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.081 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -87.73 -49.96 6.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.953 0.406 . . . . 0.0 110.346 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -84.49 -150.52 11.74 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.22 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 36' ' ' PHE . 27.7 p90 -76.95 134.95 38.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.991 0.424 . . . . 0.0 110.99 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.606 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.674 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.652 ' HA2' ' CZ ' ' A' ' 2' ' ' TYR . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.606 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -112.49 145.04 40.95 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.645 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -114.16 79.21 1.23 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.0 OUTLIER -92.99 133.65 35.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.939 -178.268 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 83.05 -87.26 0.02 OUTLIER 'General case' 0 C--O 1.231 0.116 0 CA-C-N 114.779 -1.1 . . . . 0.0 111.242 179.335 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.92 22.63 0.77 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.403 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.26 153.52 24.74 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.609 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.645 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.1 m -94.08 136.41 34.39 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 121.351 0.596 . . . . 0.0 110.742 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.3 168.37 19.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.361 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.469 HG12 ' O ' ' A' ' 6' ' ' GLY . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.527 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.49 ' O ' ' N ' ' A' ' 22' ' ' PHE . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.674 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.424 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 18' ' ' TRP . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.411 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.16 0.99 10.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -80.18 -27.64 38.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.794 0.33 . . . . 0.0 110.79 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.64 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.496 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -179.74 76.04 0.06 OUTLIER Glycine 0 C--N 1.329 0.176 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.445 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -152.22 46.15 0.74 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.354 . . . . 0.0 110.927 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.26 21.47 1.38 Allowed Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.597 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -79.28 175.1 10.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.791 0.329 . . . . 0.0 110.856 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 7.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.278 179.608 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.688 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.77 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.454 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.651 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.454 ' HB ' ' HB2' ' A' ' 3' ' ' TYR . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.688 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -109.33 149.09 29.99 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.747 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -113.23 65.24 0.65 Allowed 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.933 0.873 . . . . 0.0 110.036 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.459 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.4 t -119.15 173.96 6.61 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.059 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.459 ' O ' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 29.11 101.32 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.236 0 O-C-N 123.734 0.646 . . . . 0.0 112.375 -179.355 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER 82.02 -46.48 0.19 Allowed 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.029 179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 170.03 -134.59 3.21 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.995 -1.098 . . . . 0.0 113.295 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.747 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 30.7 m -91.6 130.46 37.41 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 121.451 0.643 . . . . 0.0 111.099 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 79.8 p -143.48 174.63 10.59 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.328 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.56 HG12 ' O ' ' A' ' 6' ' ' GLY . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.411 ' CD2' HG13 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.77 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.503 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.406 ' O ' ' CB ' ' A' ' 30' ' ' ALA . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -71.94 -32.91 67.79 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -82.66 -23.46 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.766 0.317 . . . . 0.0 111.064 -179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.84 -111.35 0.56 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.319 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.84 -66.21 0.65 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.7 m-20 -150.3 91.62 1.78 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.865 0.364 . . . . 0.0 110.811 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.443 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -61.49 -152.23 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.399 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.443 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 97.6 m-85 -161.0 154.11 21.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.774 0.321 . . . . 0.0 110.666 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.88 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.667 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.732 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.604 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 6' ' ' GLY . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.732 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -123.0 138.98 54.55 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.8 m -109.14 97.83 7.37 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.552 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.1 p -95.14 -166.44 1.46 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.007 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 -17.39 23.78 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.252 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -95.87 2.84 53.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.113 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.534 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 106.09 -157.7 15.89 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.627 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.64 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 74.7 m -90.85 132.3 35.98 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.324 0.583 . . . . 0.0 110.534 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.81 176.25 8.86 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.965 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.604 HG11 ' O ' ' A' ' 6' ' ' GLY . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.434 ' CD2' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.595 ' HB3' ' HH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.507 ' HB1' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.425 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.722 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.07 -5.06 8.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -83.01 -23.27 33.35 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.915 -0.314 . . . . 0.0 110.849 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -71.06 -79.79 0.36 Allowed Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.599 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.3 111.57 0.31 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -90.4 -27.13 19.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.789 0.328 . . . . 0.0 111.191 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.95 -117.73 5.67 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.355 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -163.12 45.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.783 0.325 . . . . 0.0 111.108 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 5.5 t90 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.923 179.638 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.602 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.621 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.488 HG21 ' O ' ' A' ' 6' ' ' GLY . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -115.67 156.36 26.04 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.4 m -128.21 81.13 2.0 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.423 0.63 . . . . 0.0 109.306 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.3 p -96.54 127.4 42.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.745 -178.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 10' ' ' THR . 1.2 mmpt? 92.42 -85.88 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 114.854 -1.066 . . . . 0.0 111.41 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 96.4 p -151.44 26.5 0.68 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.677 -179.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -167.45 158.47 31.38 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.572 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 59.1 m -96.3 140.37 31.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.548 0.689 . . . . 0.0 111.692 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -131.2 174.3 10.18 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.661 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.621 HG11 ' O ' ' A' ' 6' ' ' GLY . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.505 ' O ' ' N ' ' A' ' 22' ' ' PHE . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.413 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 18' ' ' TRP . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.687 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.411 HG21 ' CD1' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.491 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.687 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.75 -28.04 69.31 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.491 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.1 OUTLIER -83.85 -23.08 31.48 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.654 179.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.63 110.87 2.45 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.58 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.79 125.88 0.91 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.544 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.1 m-20 -87.03 -24.18 24.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.712 0.291 . . . . 0.0 111.002 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.02 25.58 2.25 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.807 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 76.59 -1.11 2.93 Favored 'General case' 0 CA--C 1.531 0.222 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 179.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 2.8 m0 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.185 -0.912 . . . . 0.0 110.887 179.919 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.848 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.636 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.401 ' O ' ' N ' ' A' ' 5' ' ' ASN . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.585 ' HA3' ' CB ' ' A' ' 21' ' ' ALA . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 6' ' ' GLY . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.848 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -108.4 150.52 27.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.646 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -115.65 93.83 4.44 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 178.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.569 ' O ' ' N ' ' A' ' 12' ' ' SER . 44.7 p -93.89 148.16 22.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.986 -177.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.476 ' HG3' ' N ' ' A' ' 12' ' ' SER . 19.1 pttt 47.08 -66.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 114.408 -1.269 . . . . 0.0 113.387 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.569 ' N ' ' O ' ' A' ' 10' ' ' THR . 29.0 t -154.59 17.08 0.46 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -152.96 150.26 22.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 119.768 -1.206 . . . . 0.0 113.372 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.646 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.0 m -93.1 133.89 35.81 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 109.998 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t -140.74 178.42 7.35 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.003 -179.251 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.516 HG11 ' CD2' ' A' ' 18' ' ' TRP . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB3' ' OE1' ' A' ' 20' ' ' GLU . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.516 ' CD2' HG11 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.636 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.585 ' CB ' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.406 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.417 ' O ' ' N ' ' A' ' 30' ' ' ALA . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.442 ' CE1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.417 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -65.98 -4.24 6.74 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.413 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 34.7 t30 -83.25 67.46 9.23 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.461 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -152.15 -81.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.572 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.1 -137.73 2.6 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.687 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -153.63 118.93 5.15 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.867 0.365 . . . . 0.0 110.962 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.28 148.62 3.83 Favored Glycine 0 CA--C 1.517 0.17 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.634 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.35 -45.64 22.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.304 . . . . 0.0 111.084 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 75.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.19 -0.909 . . . . 0.0 110.896 179.874 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.697 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.516 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.697 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -123.39 128.37 49.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.646 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.07 97.02 6.93 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.754 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.8 p -91.96 -169.97 2.42 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.832 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.428 ' HD3' ' N ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -60.03 -17.5 39.48 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.471 -179.426 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 p -93.25 -21.98 19.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.895 0.379 . . . . 0.0 110.669 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 137.64 -161.19 25.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.936 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.646 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 90.9 m -90.43 134.98 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.071 0.462 . . . . 0.0 110.219 179.294 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m -135.27 171.3 14.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.424 -179.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.498 HG11 ' CD2' ' A' ' 18' ' ' TRP . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.539 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 0.8 OUTLIER -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.498 ' CD2' HG11 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.539 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.516 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.594 HG21 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.608 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.465 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -68.7 -26.4 65.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.608 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.1 t-20 -84.07 -43.07 15.45 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.168 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 49.81 72.23 0.51 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.72 -141.65 2.95 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.559 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 49.0 m-20 -98.14 -68.43 0.8 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.06 122.92 6.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.603 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -78.17 56.76 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.747 0.308 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.2 t-105 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.691 179.575 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.579 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.772 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.772 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -138.66 132.16 30.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.606 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 35.4 m -105.09 104.21 13.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 178.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 30.2 p -97.23 -168.48 1.7 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.328 -178.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.2 pttm -61.24 -16.69 47.92 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.551 -179.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.42 -25.79 19.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.417 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.437 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 140.62 -160.57 26.55 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.619 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.606 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.1 m -92.29 128.63 38.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.202 0.525 . . . . 0.0 110.322 179.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m -136.74 -177.9 4.94 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.84 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.498 ' HB2' ' HH ' ' A' ' 2' ' ' TYR . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.443 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.443 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.417 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -72.82 -7.62 51.6 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -82.02 -24.18 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.773 0.32 . . . . 0.0 110.933 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.63 36.82 2.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.382 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.19 115.84 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.568 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.1 p-10 -89.28 -24.32 22.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.844 0.354 . . . . 0.0 110.733 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.04 150.68 13.39 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.091 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -161.69 117.59 2.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.794 0.331 . . . . 0.0 110.928 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 28.7 p90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.956 -179.975 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.718 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.575 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 6' ' ' GLY . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.718 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -115.24 135.09 54.54 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.667 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.99 75.97 1.07 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.554 0.692 . . . . 0.0 109.29 179.245 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.441 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 4.1 p -95.69 137.28 34.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.797 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 10' ' ' THR . 9.8 mttt 85.59 -87.96 0.01 OUTLIER 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.914 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.06 21.8 0.67 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.965 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -160.17 161.83 32.77 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.233 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.667 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 93.3 m -94.51 140.94 29.18 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.479 0.656 . . . . 0.0 110.928 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p -133.45 167.29 20.71 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.233 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.575 HG11 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.497 ' CD2' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.501 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.625 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.625 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.482 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.404 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.448 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.445 ' HB2' ' O ' ' A' ' 26' ' ' VAL . . . -79.31 -78.66 0.15 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 8.8 t30 43.96 71.6 0.24 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.11 0.481 . . . . 0.0 110.707 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 148.3 -79.47 0.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.624 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 52.5 45.5 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.123 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 m120 -150.6 92.41 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.799 0.333 . . . . 0.0 110.569 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 118.79 2.5 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.945 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -161.94 33.61 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.823 0.344 . . . . 0.0 110.674 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 1.8 m95 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.16 -0.924 . . . . 0.0 110.863 179.823 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.796 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.657 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.42 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.796 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -132.5 138.99 47.74 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.3 m -108.15 103.29 12.45 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 51.2 p -95.35 -168.14 1.74 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.113 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.17 -16.95 37.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.597 -179.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.97 -29.12 16.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.977 0.418 . . . . 0.0 110.481 179.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 143.97 -161.64 27.82 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 121.035 -0.603 . . . . 0.0 111.737 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.619 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.1 m -90.39 126.48 35.89 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.391 0.615 . . . . 0.0 110.752 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.53 172.46 12.68 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.87 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.549 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.415 ' HB1' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.403 ' CE1' HG21 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.833 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.438 HG12 ' HB3' ' A' ' 30' ' ' ALA . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.833 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.438 ' HB3' HG12 ' A' ' 26' ' ' VAL . . . -67.54 -12.0 59.33 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 63.4 t-20 -85.51 -39.74 17.12 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.157 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.6 -72.15 2.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.457 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 115.08 27.97 3.01 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.738 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -91.63 87.4 6.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.977 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 110.88 -175.57 18.0 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.505 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 47.88 57.01 6.44 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.892 0.377 . . . . 0.0 111.142 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.888 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.68 ' O ' HG11 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 6' ' ' GLY . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -111.18 143.95 41.12 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.675 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -116.09 77.81 1.13 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.086 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 13' ' ' GLY . 2.8 p -96.73 165.23 12.23 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.212 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.423 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 13.8 pttm 39.4 35.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.553 -1.203 . . . . 0.0 112.914 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.39 33.02 1.15 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.276 179.176 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -156.26 141.47 8.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.477 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.675 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 5.8 m -91.36 137.68 32.18 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.442 0.639 . . . . 0.0 110.696 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 88.4 p -141.65 167.46 22.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.453 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.68 HG11 ' O ' ' A' ' 6' ' ' GLY . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.435 ' CG ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.404 ' HB3' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.694 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.464 ' CG2' ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.492 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.694 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.455 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -70.01 -6.5 33.89 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.492 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 31.0 t30 -80.76 -23.95 38.99 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.682 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -68.2 -65.88 2.52 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.184 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.7 -83.73 0.11 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -152.06 -42.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.696 0.284 . . . . 0.0 111.012 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.451 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -162.53 73.19 0.19 Allowed Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.536 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.451 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 91.9 m-85 -161.06 70.87 0.39 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.821 0.343 . . . . 0.0 110.542 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.845 179.958 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.605 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.781 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.444 ' HD2' HG13 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.639 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG13 ' HD2' ' A' ' 3' ' ' TYR . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.781 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -118.15 147.31 43.45 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.653 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 10.8 m -116.86 86.76 2.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.409 0.623 . . . . 0.0 110.03 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.87 ' O ' ' N ' ' A' ' 12' ' ' SER . 17.6 p -98.62 129.55 45.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.683 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 10.2 mttt 25.08 -54.44 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.87 ' N ' ' O ' ' A' ' 10' ' ' THR . 81.4 p -80.72 3.08 23.41 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.637 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 115.93 -159.99 13.57 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.318 -0.944 . . . . 0.0 112.713 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.653 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 60.7 m -91.69 134.65 34.52 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.505 0.669 . . . . 0.0 110.961 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m -138.6 172.12 13.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.648 -1.16 . . . . 0.0 109.983 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 6' ' ' GLY . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.411 ' CD2' HG11 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.521 ' O ' HG21 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.521 HG21 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.471 ' O ' ' CA ' ' A' ' 31' ' ' ASN . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -72.45 -54.31 9.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' CA ' ' O ' ' A' ' 27' ' ' HIS . 7.4 p30 45.24 32.85 1.04 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.651 179.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.58 -84.28 0.06 OUTLIER Glycine 0 C--N 1.331 0.304 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.588 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.58 100.45 0.22 Allowed Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.881 -0.675 . . . . 0.0 112.363 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.9 p30 45.33 76.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.971 0.415 . . . . 0.0 110.946 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.93 -118.84 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.64 -179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -163.31 -78.85 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.706 0.289 . . . . 0.0 110.787 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.232 -0.889 . . . . 0.0 110.689 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' TYR . . . . . 0.714 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.493 ' HD2' HG11 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.636 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.493 HG11 ' HD2' ' A' ' 3' ' ' TYR . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.714 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -110.26 135.76 50.52 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.709 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.11 78.1 1.28 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.639 0.733 . . . . 0.0 109.912 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.484 ' O ' ' N ' ' A' ' 12' ' ' SER . 5.4 p -96.5 -166.59 1.44 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.61 -1.177 . . . . 0.0 111.701 -178.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 37.27 -85.09 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.962 -1.017 . . . . 0.0 112.574 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 10' ' ' THR . 0.3 OUTLIER -149.3 21.31 0.95 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.47 -179.492 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -172.68 -175.88 40.93 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.474 -0.87 . . . . 0.0 112.71 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.709 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 23.1 m -94.97 142.0 27.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.484 0.659 . . . . 0.0 111.584 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.0 m -137.74 161.07 37.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.084 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.413 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.51 ' O ' ' N ' ' A' ' 22' ' ' PHE . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.823 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.823 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.456 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.526 ' HB1' ' O ' ' A' ' 26' ' ' VAL . . . -69.84 -21.17 63.38 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.456 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -80.67 -26.49 37.57 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.753 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -85.09 -89.82 0.86 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.096 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.43 56.81 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.293 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 53.74 95.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.641 0.258 . . . . 0.0 111.006 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.497 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -172.54 111.42 0.39 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.974 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.497 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 15.9 p90 50.67 173.56 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.112 0.482 . . . . 0.0 111.833 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.694 -179.418 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.607 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.769 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.535 ' O ' HG23 ' A' ' 7' ' ' VAL . 0.5 OUTLIER -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.953 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG22 ' A' ' 16' ' ' VAL . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.607 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.607 0.241 . . . . 0.0 110.651 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.953 HG13 ' O ' ' A' ' 6' ' ' GLY . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.446 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.799 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.769 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.905 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.679 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.713 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.727 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.437 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.7 OUTLIER -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.833 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 16' ' ' VAL . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.713 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.572 0.225 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 7' ' ' VAL . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.414 ' CB ' ' HB2' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.759 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.533 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.833 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.882 ' O ' HG23 ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.838 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.882 HG23 ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.412 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.838 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.417 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.83 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 16' ' ' VAL . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.576 ' CE1' ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 CA--C 1.518 -0.257 0 CA-C-O 120.74 0.305 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 7' ' ' VAL . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.447 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.6 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.814 ' H ' HG12 ' A' ' 16' ' ' VAL . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.83 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.782 ' O ' HG23 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.519 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.897 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.757 HG22 HG22 ' A' ' 16' ' ' VAL . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.607 ' N ' ' O ' ' A' ' 8' ' ' HIS . 42.9 m . . . . . 0 CA--C 1.513 -0.467 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.049 HG12 ' H ' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 1.049 ' H ' HG12 ' A' ' 16' ' ' VAL . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.43 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.446 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.791 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.628 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.628 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.537 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.0 OUTLIER -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.962 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.796 HG22 HG22 ' A' ' 16' ' ' VAL . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.784 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 8' ' ' HIS . 12.0 p . . . . . 0 CA--C 1.521 -0.14 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.911 ' H ' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.665 ' C ' HD13 ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.611 ' N ' HD13 ' A' ' 29' ' ' LEU . . . . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.74 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.619 ' CE2' ' HA2' ' A' ' 6' ' ' GLY . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.684 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.741 HG22 ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.74 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.534 ' O ' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 18' ' ' TRP . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.736 ' H ' ' HE1' ' A' ' 8' ' ' HIS . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.616 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.85 ' O ' HG23 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.437 ' CE1' ' O ' ' A' ' 23' ' ' SER . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.695 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.701 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 16' ' ' VAL . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.615 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.635 0.255 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 7' ' ' VAL . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.495 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.795 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.695 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.701 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.918 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.702 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.78 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.476 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.694 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 16' ' ' VAL . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.702 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 8' ' ' HIS . 79.8 p . . . . . 0 N--CA 1.454 -0.263 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 7' ' ' VAL . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.824 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.78 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.599 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.873 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.681 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.555 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.865 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 16' ' ' VAL . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.681 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.186 0 CA-C-O 120.695 0.283 . . . . 0.0 110.965 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 7' ' ' VAL . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.415 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.3 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.728 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.555 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.525 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.738 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.738 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.62 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.542 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.907 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 16' ' ' VAL . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.62 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 8' ' ' HIS . 2.4 t . . . . . 0 N--CA 1.455 -0.191 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 7' ' ' VAL . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.711 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.487 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.833 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.702 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.425 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.702 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.863 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.652 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.41 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 1.013 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.827 HG22 HG22 ' A' ' 16' ' ' VAL . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.863 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t . . . . . 0 CA--C 1.523 -0.085 0 CA-C-O 120.654 0.264 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.013 HG13 ' O ' ' A' ' 6' ' ' GLY . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.443 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.677 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.652 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.775 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 22' ' ' PHE . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.442 ' CE1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.503 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.862 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.763 HG22 HG22 ' A' ' 16' ' ' VAL . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.57 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.424 -0.213 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 6' ' ' GLY . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 17.1 t-20 -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.737 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.568 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.552 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.579 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.574 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.699 HG22 HG22 ' A' ' 16' ' ' VAL . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.593 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.577 0.227 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.787 HG12 ' H ' ' A' ' 18' ' ' TRP . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.787 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.931 ' O ' HG23 ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.511 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.521 ' O ' HG23 ' A' ' 7' ' ' VAL . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.925 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.905 HG22 HG22 ' A' ' 16' ' ' VAL . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.571 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.925 HG13 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.678 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.531 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.621 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.462 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.409 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.45 ' N ' ' HG ' ' A' ' 29' ' ' LEU . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.808 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.552 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.433 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 16' ' ' VAL . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.808 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 7' ' ' VAL . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.487 ' HB2' ' HE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.817 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.552 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.419 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.794 ' O ' HG23 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.849 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.575 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.592 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.9 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 16' ' ' VAL . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.592 ' CE1' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 8' ' ' HIS . 88.4 p . . . . . 0 CA--C 1.519 -0.232 0 CA-C-O 120.653 0.263 . . . . 0.0 110.453 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 7' ' ' VAL . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.684 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.711 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.459 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.711 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.626 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.573 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.425 ' HD2' HG12 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.858 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 16' ' ' VAL . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.626 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 7' ' ' VAL . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.723 ' H ' HG12 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.42 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' CG ' ' O ' ' A' ' 23' ' ' SER . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' TYR . . . . . 0.666 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.982 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.744 HG22 HG22 ' A' ' 16' ' ' VAL . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.666 ' CE1' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.457 ' N ' ' O ' ' A' ' 8' ' ' HIS . 4.0 m . . . . . 0 CA--C 1.521 -0.15 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.982 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.613 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.405 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.886 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.886 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.607 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.769 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.535 ' O ' HG23 ' A' ' 7' ' ' VAL . 0.5 OUTLIER -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.953 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG22 ' A' ' 16' ' ' VAL . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.607 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -128.04 147.57 50.52 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.8 m -109.67 97.88 7.34 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.703 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 69.3 p -98.91 158.35 15.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.08 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 36.1 34.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.409 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p 74.04 47.0 0.16 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.424 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -161.92 127.19 1.68 Allowed Glycine 0 N--CA 1.452 -0.288 0 N-CA-C 111.466 -0.653 . . . . 0.0 111.466 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 57.0 m -88.47 126.6 35.32 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 121.476 0.655 . . . . 0.0 111.22 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -146.62 173.74 12.06 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.651 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.953 HG13 ' O ' ' A' ' 6' ' ' GLY . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.446 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.799 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.769 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.905 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.679 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.87 -1.18 10.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -82.02 -35.23 29.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.85 0.357 . . . . 0.0 110.922 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -82.48 59.7 4.91 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.551 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.408 ' O ' ' N ' ' A' ' 35' ' ' GLY . . . -99.18 78.55 0.52 Allowed Glycine 0 CA--C 1.517 0.213 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.674 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 66.11 -61.12 0.29 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.408 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -148.48 -145.97 4.25 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.678 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER 55.64 80.77 0.13 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.75 0.309 . . . . 0.0 110.915 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.896 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.713 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.727 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.437 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.7 OUTLIER -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.833 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 16' ' ' VAL . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.713 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -111.09 161.27 16.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 18.8 m -124.31 85.9 2.48 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.299 0.571 . . . . 0.0 109.831 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.766 ' O ' ' N ' ' A' ' 12' ' ' SER . 6.8 p -103.97 143.86 32.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.158 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 mmmm 22.55 -61.46 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 178.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.766 ' N ' ' O ' ' A' ' 10' ' ' THR . 59.1 p -81.82 3.49 25.76 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -177.609 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.652 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 114.9 -155.29 16.44 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.94 178.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 61.4 m -92.5 127.52 38.02 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.542 0.687 . . . . 0.0 111.52 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p -146.47 170.52 16.68 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.494 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 7' ' ' VAL . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.414 ' CB ' ' HB2' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.759 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.533 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.833 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.882 ' O ' HG23 ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.838 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.882 HG23 ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.486 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.838 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -66.67 -21.05 66.1 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.486 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.7 t30 -83.71 62.26 6.78 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 150.35 -21.94 1.08 Allowed Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.828 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -153.83 113.96 0.6 Allowed Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.534 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -150.78 102.38 2.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.112 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.96 35.32 3.85 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.207 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -77.61 129.67 35.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.837 0.351 . . . . 0.0 111.107 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 3.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.154 -0.927 . . . . 0.0 110.94 179.582 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.417 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.83 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 16' ' ' VAL . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.576 ' CE1' ' O ' ' A' ' 6' ' ' GLY . 0.0 OUTLIER -120.12 151.0 39.7 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.3 m -113.54 87.59 2.64 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.3 p -91.36 133.91 35.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.679 -178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.6 tttt 77.73 -84.27 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.44 22.68 0.54 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.5 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -152.98 147.05 16.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.163 -1.018 . . . . 0.0 112.885 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 53.6 m -92.31 128.29 38.11 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-O 121.364 0.602 . . . . 0.0 110.731 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m -145.99 152.51 39.5 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.683 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 7' ' ' VAL . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.447 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.6 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.814 ' H ' HG12 ' A' ' 16' ' ' VAL . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.83 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.782 ' O ' HG23 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -74.26 -18.35 60.74 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.436 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 1.1 t30 -76.33 82.13 3.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.069 0.461 . . . . 0.0 110.794 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -177.66 -46.65 0.07 OUTLIER Glycine 0 C--N 1.331 0.271 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.28 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.64 4.48 34.64 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.005 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -89.8 -46.96 8.22 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.833 0.317 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 163.46 124.64 0.72 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.893 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 72.29 -155.83 0.09 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 120.48 0.181 . . . . 0.0 111.268 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.3 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.519 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.897 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.757 HG22 HG22 ' A' ' 16' ' ' VAL . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -109.51 151.26 26.98 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.678 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -119.39 78.21 1.28 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.499 0.666 . . . . 0.0 109.758 179.869 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.593 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -94.14 135.42 35.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.508 -179.249 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.593 ' HB2' ' O ' ' A' ' 10' ' ' THR . 5.0 mmmt 83.21 -89.68 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.555 179.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 p -149.61 20.79 0.92 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.539 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.16 159.72 29.9 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.743 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.678 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 35.5 m -93.17 132.74 37.04 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.609 0.718 . . . . 0.0 110.926 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.534 ' N ' ' O ' ' A' ' 8' ' ' HIS . 42.9 m -111.27 -178.46 3.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.999 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.049 HG12 ' H ' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 1.049 ' H ' HG12 ' A' ' 16' ' ' VAL . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.43 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.446 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.791 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.628 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.446 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.628 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -64.85 -15.36 61.76 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.446 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 16.4 t30 -84.52 -36.56 22.11 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.935 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 48.8 97.86 0.01 OUTLIER Glycine 0 CA--C 1.519 0.341 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.061 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . 96.71 149.18 25.23 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.166 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -82.38 69.26 9.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.095 0.474 . . . . 0.0 110.21 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.8 -36.88 24.38 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.06 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 77.42 112.22 0.07 Allowed 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 120.67 0.272 . . . . 0.0 110.696 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.688 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.537 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.0 OUTLIER -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.962 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.796 HG22 HG22 ' A' ' 16' ' ' VAL . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.784 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -120.44 151.25 39.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.4 m -127.21 92.07 3.45 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.52 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.5 p -96.17 118.25 32.37 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.665 -178.415 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.52 ' HB2' ' O ' ' A' ' 10' ' ' THR . 2.1 mmmp? 87.57 -85.38 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.505 179.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.0 p -150.49 31.89 0.65 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.478 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -159.89 143.91 9.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.002 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 62.0 m -97.59 139.55 33.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.573 0.702 . . . . 0.0 111.726 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 p -125.7 171.62 10.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.065 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.911 ' H ' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.501 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.665 HD13 ' C ' ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.611 ' N ' HD13 ' A' ' 29' ' ' LEU . . . -67.04 -22.63 65.86 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.501 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.5 t30 -80.79 68.85 7.18 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.542 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.7 96.94 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.251 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.09 118.42 3.97 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.762 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -150.93 -46.86 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.841 0.353 . . . . 0.0 110.662 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 86.08 140.66 5.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.714 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -162.21 35.43 0.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.85 0.357 . . . . 0.0 110.549 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.2 m-90 . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.908 -179.983 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.74 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.619 ' CE2' ' HA2' ' A' ' 6' ' ' GLY . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.684 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.741 HG22 ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.74 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -139.7 127.15 21.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.3 OUTLIER -106.44 89.35 3.01 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.421 0.629 . . . . 0.0 110.004 179.139 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -96.89 -167.53 1.56 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.274 -179.164 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' N ' ' OG1' ' A' ' 10' ' ' THR . 0.0 OUTLIER -56.47 -21.22 24.19 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.454 -178.91 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 91.1 p -94.04 16.6 14.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.366 178.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 90.6 -155.94 24.4 Favored Glycine 0 C--N 1.333 0.403 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.729 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 45.7 m -90.86 131.1 36.7 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.534 ' O ' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -150.21 110.94 4.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 -179.35 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 18' ' ' TRP . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.736 ' H ' ' HE1' ' A' ' 8' ' ' HIS . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.616 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.85 ' O ' HG23 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.453 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.83 -29.96 66.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.6 t-20 -81.24 59.39 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.051 0.453 . . . . 0.0 110.767 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 72.48 0.57 Allowed Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.329 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.02 -37.99 0.14 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.081 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -87.73 -49.96 6.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.953 0.406 . . . . 0.0 110.346 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -84.49 -150.52 11.74 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.22 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 36' ' ' PHE . 27.7 p90 -76.95 134.95 38.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.991 0.424 . . . . 0.0 110.99 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.695 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.701 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 16' ' ' VAL . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.615 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -112.49 145.04 40.95 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.696 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -114.16 79.21 1.23 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.978 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.0 OUTLIER -92.99 133.65 35.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.939 -178.268 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 83.05 -87.26 0.02 OUTLIER 'General case' 0 C--O 1.231 0.116 0 CA-C-N 114.779 -1.1 . . . . 0.0 111.242 179.335 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.92 22.63 0.77 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.403 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.26 153.52 24.74 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.609 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.696 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.1 m -94.08 136.41 34.39 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 121.351 0.596 . . . . 0.0 110.742 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.3 168.37 19.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.361 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 7' ' ' VAL . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.495 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.795 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.695 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.701 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.918 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -73.16 0.99 10.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -80.18 -27.64 38.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.794 0.33 . . . . 0.0 110.79 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.64 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.496 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -179.74 76.04 0.06 OUTLIER Glycine 0 C--N 1.329 0.176 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.445 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -152.22 46.15 0.74 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.354 . . . . 0.0 110.927 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.26 21.47 1.38 Allowed Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.597 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -79.28 175.1 10.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.791 0.329 . . . . 0.0 110.856 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 7.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.278 179.608 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.702 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.78 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.476 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.694 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 16' ' ' VAL . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.702 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -109.33 149.09 29.99 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.799 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -113.23 65.24 0.65 Allowed 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.933 0.873 . . . . 0.0 110.036 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.459 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.4 t -119.15 173.96 6.61 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.059 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.459 ' O ' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 29.11 101.32 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.236 0 O-C-N 123.734 0.646 . . . . 0.0 112.375 -179.355 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER 82.02 -46.48 0.19 Allowed 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.029 179.986 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 170.03 -134.59 3.21 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.995 -1.098 . . . . 0.0 113.295 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.799 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 30.7 m -91.6 130.46 37.41 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 121.451 0.643 . . . . 0.0 111.099 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 79.8 p -143.48 174.63 10.59 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.328 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 7' ' ' VAL . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.824 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.78 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.599 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.873 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -71.94 -32.91 67.79 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -82.66 -23.46 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.766 0.317 . . . . 0.0 111.064 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.84 -111.35 0.56 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.319 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.84 -66.21 0.65 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.7 m-20 -150.3 91.62 1.78 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.865 0.364 . . . . 0.0 110.811 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.443 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -61.49 -152.23 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.399 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.443 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 97.6 m-85 -161.0 154.11 21.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.774 0.321 . . . . 0.0 110.666 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.88 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.681 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.555 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.865 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 16' ' ' VAL . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.681 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -123.0 138.98 54.55 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.683 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.8 m -109.14 97.83 7.37 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.552 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.1 p -95.14 -166.44 1.46 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.007 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 -17.39 23.78 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.252 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -95.87 2.84 53.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.113 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.554 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 106.09 -157.7 15.89 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.627 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.683 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 74.7 m -90.85 132.3 35.98 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.324 0.583 . . . . 0.0 110.534 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.81 176.25 8.86 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.965 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 7' ' ' VAL . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.415 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.3 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.728 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.555 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.525 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.738 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.738 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -66.07 -5.06 8.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -83.01 -23.27 33.35 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.915 -0.314 . . . . 0.0 110.849 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -71.06 -79.79 0.36 Allowed Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.599 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.3 111.57 0.31 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -90.4 -27.13 19.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.789 0.328 . . . . 0.0 111.191 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.95 -117.73 5.67 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.355 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -163.12 45.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.783 0.325 . . . . 0.0 111.108 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 5.5 t90 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.923 179.638 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.62 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.542 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.907 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 16' ' ' VAL . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.62 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -115.67 156.36 26.04 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.4 m -128.21 81.13 2.0 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.423 0.63 . . . . 0.0 109.306 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.3 p -96.54 127.4 42.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.745 -178.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 10' ' ' THR . 1.2 mmpt? 92.42 -85.88 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 114.854 -1.066 . . . . 0.0 111.41 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 96.4 p -151.44 26.5 0.68 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.677 -179.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -167.45 158.47 31.38 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.572 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 59.1 m -96.3 140.37 31.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.548 0.689 . . . . 0.0 111.692 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -131.2 174.3 10.18 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.661 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 7' ' ' VAL . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.711 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.487 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.833 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.702 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.526 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.702 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -64.75 -28.04 69.31 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.1 OUTLIER -83.85 -23.08 31.48 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.654 179.716 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.63 110.87 2.45 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.58 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.79 125.88 0.91 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.544 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.1 m-20 -87.03 -24.18 24.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.712 0.291 . . . . 0.0 111.002 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.02 25.58 2.25 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.807 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 76.59 -1.11 2.93 Favored 'General case' 0 CA--C 1.531 0.222 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 2.8 m0 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.185 -0.912 . . . . 0.0 110.887 179.919 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.863 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.652 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.41 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 1.013 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.827 HG22 HG22 ' A' ' 16' ' ' VAL . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.863 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -108.4 150.52 27.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -115.65 93.83 4.44 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 178.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.578 ' O ' ' N ' ' A' ' 12' ' ' SER . 44.7 p -93.89 148.16 22.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.986 -177.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.496 ' HG3' ' N ' ' A' ' 12' ' ' SER . 19.1 pttt 47.08 -66.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 114.408 -1.269 . . . . 0.0 113.387 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.578 ' N ' ' O ' ' A' ' 10' ' ' THR . 29.0 t -154.59 17.08 0.46 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -152.96 150.26 22.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 119.768 -1.206 . . . . 0.0 113.372 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.0 m -93.1 133.89 35.81 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 109.998 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t -140.74 178.42 7.35 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.003 -179.251 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.013 HG13 ' O ' ' A' ' 6' ' ' GLY . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.443 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.677 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.652 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.775 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 22' ' ' PHE . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.447 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -65.98 -4.24 6.74 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 34.7 t30 -83.25 67.46 9.23 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.461 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -152.15 -81.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.572 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.1 -137.73 2.6 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.687 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -153.63 118.93 5.15 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.867 0.365 . . . . 0.0 110.962 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.28 148.62 3.83 Favored Glycine 0 CA--C 1.517 0.17 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.634 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.35 -45.64 22.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.304 . . . . 0.0 111.084 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 75.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.19 -0.909 . . . . 0.0 110.896 179.874 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.503 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.862 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.763 HG22 HG22 ' A' ' 16' ' ' VAL . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.57 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -123.39 128.37 49.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.688 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.07 97.02 6.93 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.754 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.8 p -91.96 -169.97 2.42 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.832 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.44 ' HD3' ' N ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -60.03 -17.5 39.48 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.471 -179.426 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 p -93.25 -21.98 19.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.895 0.379 . . . . 0.0 110.669 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 137.64 -161.19 25.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.936 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.688 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 90.9 m -90.43 134.98 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.071 0.462 . . . . 0.0 110.219 179.294 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m -135.27 171.3 14.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.424 -179.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 6' ' ' GLY . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 17.1 t-20 -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.737 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.568 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.552 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.637 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.7 -26.4 65.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.637 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.1 t-20 -84.07 -43.07 15.45 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.168 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 49.81 72.23 0.51 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.72 -141.65 2.95 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.559 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 49.0 m-20 -98.14 -68.43 0.8 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.06 122.92 6.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.603 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -78.17 56.76 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.747 0.308 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.2 t-105 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.691 179.575 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.579 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.574 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.699 HG22 HG22 ' A' ' 16' ' ' VAL . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.593 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -138.66 132.16 30.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 35.4 m -105.09 104.21 13.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 178.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 30.2 p -97.23 -168.48 1.7 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.328 -178.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.2 pttm -61.24 -16.69 47.92 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.551 -179.3 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.42 -25.79 19.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.417 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 140.62 -160.57 26.55 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.619 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.1 m -92.29 128.63 38.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.202 0.525 . . . . 0.0 110.322 179.129 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m -136.74 -177.9 4.94 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.84 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.787 HG12 ' H ' ' A' ' 18' ' ' TRP . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.787 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.931 ' O ' HG23 ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -72.82 -7.62 51.6 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -82.02 -24.18 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.773 0.32 . . . . 0.0 110.933 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.63 36.82 2.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.382 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.19 115.84 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.568 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.1 p-10 -89.28 -24.32 22.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.844 0.354 . . . . 0.0 110.733 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.04 150.68 13.39 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.091 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -161.69 117.59 2.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.794 0.331 . . . . 0.0 110.928 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 28.7 p90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.956 -179.975 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.511 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.521 ' O ' HG23 ' A' ' 7' ' ' VAL . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.925 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.905 HG22 HG22 ' A' ' 16' ' ' VAL . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.571 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -115.24 135.09 54.54 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.99 75.97 1.07 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.554 0.692 . . . . 0.0 109.29 179.245 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 4.1 p -95.69 137.28 34.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.797 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 10' ' ' THR . 9.8 mttt 85.59 -87.96 0.01 OUTLIER 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.914 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.06 21.8 0.67 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.965 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -160.17 161.83 32.77 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.233 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 93.3 m -94.51 140.94 29.18 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.479 0.656 . . . . 0.0 110.928 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p -133.45 167.29 20.71 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.233 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.925 HG13 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.678 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.531 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.621 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.51 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.409 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.45 ' N ' ' HG ' ' A' ' 29' ' ' LEU . . . -79.31 -78.66 0.15 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.51 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 8.8 t30 43.96 71.6 0.24 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.11 0.481 . . . . 0.0 110.707 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 148.3 -79.47 0.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.624 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 52.5 45.5 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.123 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 m120 -150.6 92.41 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.799 0.333 . . . . 0.0 110.569 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 118.79 2.5 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.945 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -161.94 33.61 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.823 0.344 . . . . 0.0 110.674 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 1.8 m95 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.16 -0.924 . . . . 0.0 110.863 179.823 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.808 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.552 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.433 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 16' ' ' VAL . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.808 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -132.5 138.99 47.74 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.666 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.3 m -108.15 103.29 12.45 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.777 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 51.2 p -95.35 -168.14 1.74 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.113 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.17 -16.95 37.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.597 -179.148 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.97 -29.12 16.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.977 0.418 . . . . 0.0 110.481 179.19 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 143.97 -161.64 27.82 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 121.035 -0.603 . . . . 0.0 111.737 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.666 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.1 m -90.39 126.48 35.89 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.391 0.615 . . . . 0.0 110.752 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.53 172.46 12.68 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.87 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 7' ' ' VAL . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.487 ' HB2' ' HE1' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.817 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.552 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.419 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.794 ' O ' HG23 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.849 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -67.54 -12.0 59.33 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 63.4 t-20 -85.51 -39.74 17.12 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.157 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.6 -72.15 2.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.457 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 115.08 27.97 3.01 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.738 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -91.63 87.4 6.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.977 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 110.88 -175.57 18.0 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.505 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 47.88 57.01 6.44 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.892 0.377 . . . . 0.0 111.142 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.888 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.575 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.592 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.9 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 16' ' ' VAL . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.592 ' CE1' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -111.18 143.95 41.12 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -116.09 77.81 1.13 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.086 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 13' ' ' GLY . 2.8 p -96.73 165.23 12.23 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.212 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.414 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 13.8 pttm 39.4 35.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.553 -1.203 . . . . 0.0 112.914 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.39 33.02 1.15 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.276 179.176 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -156.26 141.47 8.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.477 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 5.8 m -91.36 137.68 32.18 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.442 0.639 . . . . 0.0 110.696 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 88.4 p -141.65 167.46 22.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.453 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 7' ' ' VAL . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.684 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.711 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.525 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.711 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.01 -6.5 33.89 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.525 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 31.0 t30 -80.76 -23.95 38.99 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.682 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -68.2 -65.88 2.52 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.184 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.7 -83.73 0.11 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -152.06 -42.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.696 0.284 . . . . 0.0 111.012 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.451 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -162.53 73.19 0.19 Allowed Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.536 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.451 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 91.9 m-85 -161.06 70.87 0.39 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.821 0.343 . . . . 0.0 110.542 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.845 179.958 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.626 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.573 ' CE1' ' ND1' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.425 ' HD2' HG12 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.858 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 16' ' ' VAL . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.626 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -118.15 147.31 43.45 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.701 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 10.8 m -116.86 86.76 2.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.409 0.623 . . . . 0.0 110.03 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.87 ' O ' ' N ' ' A' ' 12' ' ' SER . 17.6 p -98.62 129.55 45.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.683 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 10.2 mttt 25.08 -54.44 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 178.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.87 ' N ' ' O ' ' A' ' 10' ' ' THR . 81.4 p -80.72 3.08 23.41 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 115.93 -159.99 13.57 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.318 -0.944 . . . . 0.0 112.713 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.701 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 60.7 m -91.69 134.65 34.52 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.505 0.669 . . . . 0.0 110.961 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m -138.6 172.12 13.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.648 -1.16 . . . . 0.0 109.983 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 7' ' ' VAL . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.723 ' H ' HG12 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.42 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.471 ' O ' ' CA ' ' A' ' 31' ' ' ASN . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -72.45 -54.31 9.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' CA ' ' O ' ' A' ' 27' ' ' HIS . 7.4 p30 45.24 32.85 1.04 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.651 179.571 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.58 -84.28 0.06 OUTLIER Glycine 0 C--N 1.331 0.304 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.588 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.58 100.45 0.22 Allowed Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.881 -0.675 . . . . 0.0 112.363 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.9 p30 45.33 76.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.971 0.415 . . . . 0.0 110.946 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.93 -118.84 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.64 -179.514 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -163.31 -78.85 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.706 0.289 . . . . 0.0 110.787 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.232 -0.889 . . . . 0.0 110.689 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' TYR . . . . . 0.666 ' CE1' ' CE1' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.982 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.744 HG22 HG22 ' A' ' 16' ' ' VAL . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.666 ' CE1' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -110.26 135.76 50.52 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.749 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.11 78.1 1.28 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.639 0.733 . . . . 0.0 109.912 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.484 ' O ' ' N ' ' A' ' 12' ' ' SER . 5.4 p -96.5 -166.59 1.44 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.61 -1.177 . . . . 0.0 111.701 -178.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 37.27 -85.09 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.962 -1.017 . . . . 0.0 112.574 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 10' ' ' THR . 0.3 OUTLIER -149.3 21.31 0.95 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.47 -179.492 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -172.68 -175.88 40.93 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.474 -0.87 . . . . 0.0 112.71 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.749 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 23.1 m -94.97 142.0 27.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.484 0.659 . . . . 0.0 111.584 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.0 m -137.74 161.07 37.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.084 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.982 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.613 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.405 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.886 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.886 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.489 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.84 -21.17 63.38 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.489 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -80.67 -26.49 37.57 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.753 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -85.09 -89.82 0.86 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.096 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.43 56.81 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.293 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 53.74 95.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.641 0.258 . . . . 0.0 111.006 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.497 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -172.54 111.42 0.39 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.974 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.497 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 15.9 p90 50.67 173.56 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.112 0.482 . . . . 0.0 111.833 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.694 -179.418 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.607 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.769 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.535 ' O ' HG23 ' A' ' 7' ' ' VAL . 1.6 m-20 -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.953 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG22 ' A' ' 16' ' ' VAL . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.686 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.607 0.241 . . . . 0.0 110.651 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.953 HG13 ' O ' ' A' ' 6' ' ' GLY . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.454 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.799 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.769 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.905 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.679 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.713 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.727 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.437 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 2.8 m-20 -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.833 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 16' ' ' VAL . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.713 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.572 0.225 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 7' ' ' VAL . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.466 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.759 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.533 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.833 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.882 ' O ' HG23 ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.838 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.882 HG23 ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.412 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.838 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.521 ' CD1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.417 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.83 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 16' ' ' VAL . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.596 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 CA--C 1.518 -0.257 0 CA-C-O 120.74 0.305 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 7' ' ' VAL . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.552 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.814 ' H ' HG12 ' A' ' 16' ' ' VAL . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.83 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.782 ' O ' HG23 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.519 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.897 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.757 HG22 HG22 ' A' ' 16' ' ' VAL . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.607 ' N ' ' O ' ' A' ' 8' ' ' HIS . 42.9 m . . . . . 0 CA--C 1.513 -0.467 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.049 HG12 ' H ' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 1.049 ' H ' HG12 ' A' ' 16' ' ' VAL . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.43 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.446 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.791 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.628 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.628 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.733 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.6 m120 -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.962 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.796 HG22 HG22 ' A' ' 16' ' ' VAL . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.784 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 8' ' ' HIS . 12.0 p . . . . . 0 CA--C 1.521 -0.14 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.911 ' H ' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.665 ' C ' HD13 ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.611 ' N ' HD13 ' A' ' 29' ' ' LEU . . . . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.74 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.724 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.684 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.741 HG22 ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.74 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.43 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 18' ' ' TRP . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.616 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.616 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.85 ' O ' HG23 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.437 ' CE1' ' O ' ' A' ' 23' ' ' SER . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.695 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.701 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 16' ' ' VAL . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.615 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.635 0.255 . . . . 0.0 110.361 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 7' ' ' VAL . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.528 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.795 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.695 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.701 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.918 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.702 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.78 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.476 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.694 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 16' ' ' VAL . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.702 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 8' ' ' HIS . 79.8 p . . . . . 0 N--CA 1.454 -0.263 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 7' ' ' VAL . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.824 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.78 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.599 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.873 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.681 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.732 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.865 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 16' ' ' VAL . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.732 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.186 0 CA-C-O 120.695 0.283 . . . . 0.0 110.965 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 7' ' ' VAL . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.415 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.728 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.555 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.525 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.738 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.738 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.62 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.907 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 16' ' ' VAL . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 8' ' ' HIS . 2.4 t . . . . . 0 N--CA 1.455 -0.191 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 7' ' ' VAL . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.711 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.487 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.833 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.702 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.425 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.702 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.863 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.652 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.41 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 1.013 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.827 HG22 HG22 ' A' ' 16' ' ' VAL . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.863 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t . . . . . 0 CA--C 1.523 -0.085 0 CA-C-O 120.654 0.264 . . . . 0.0 111.003 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.013 HG13 ' O ' ' A' ' 6' ' ' GLY . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB3' ' OE1' ' A' ' 20' ' ' GLU . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.677 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.652 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.775 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 22' ' ' PHE . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.442 ' CE1' ' O ' ' A' ' 23' ' ' SER . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.697 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.862 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.763 HG22 HG22 ' A' ' 16' ' ' VAL . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.697 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.424 -0.213 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 6' ' ' GLY . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 0.8 OUTLIER -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.737 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.568 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.552 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.448 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.772 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.574 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.699 HG22 HG22 ' A' ' 16' ' ' VAL . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.772 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m . . . . . 0 CA--C 1.519 -0.222 0 CA-C-O 120.577 0.227 . . . . 0.0 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.787 HG12 ' H ' ' A' ' 18' ' ' TRP . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.787 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.931 ' O ' HG23 ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.718 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.521 ' O ' HG23 ' A' ' 7' ' ' VAL . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.925 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.905 HG22 HG22 ' A' ' 16' ' ' VAL . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.718 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.453 -0.289 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.925 HG13 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.678 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.531 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.621 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.462 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.409 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.45 ' N ' ' HG ' ' A' ' 29' ' ' LEU . . . . . . . . 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.808 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.657 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.433 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 16' ' ' VAL . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.808 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 120.839 0.352 . . . . 0.0 110.87 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 7' ' ' VAL . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB2' ' OE1' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.817 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.552 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.419 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.794 ' O ' HG23 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.849 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.451 ' ND1' ' O ' ' A' ' 23' ' ' SER . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.575 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.9 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 16' ' ' VAL . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.443 ' N ' ' O ' ' A' ' 8' ' ' HIS . 88.4 p . . . . . 0 CA--C 1.519 -0.232 0 CA-C-O 120.653 0.263 . . . . 0.0 110.453 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 7' ' ' VAL . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.684 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.711 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.459 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.711 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.626 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.781 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.425 ' HD2' HG12 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.858 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 16' ' ' VAL . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.781 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 7' ' ' VAL . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.723 ' H ' HG12 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.42 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.426 ' CG ' ' O ' ' A' ' 23' ' ' SER . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' TYR . . . . . 0.714 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.982 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.744 HG22 HG22 ' A' ' 16' ' ' VAL . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.714 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.457 ' N ' ' O ' ' A' ' 8' ' ' HIS . 4.0 m . . . . . 0 CA--C 1.521 -0.15 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.982 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.613 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.405 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.886 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.886 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.607 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 8.2 ptpt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.54 0.21 . . . . 0.0 111.425 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.769 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.5 OUTLIER -80.57 139.73 36.15 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 179.84 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -109.73 40.34 1.92 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.081 0.467 . . . . 0.0 110.322 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.99 18.78 0.3 Allowed Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.845 -0.616 . . . . 0.0 113.161 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.535 ' O ' HG23 ' A' ' 7' ' ' VAL . 1.6 m-20 -145.8 52.42 1.16 Allowed 'General case' 0 C--O 1.233 0.196 0 CA-C-O 120.596 0.236 . . . . 0.0 110.629 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.953 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 42.07 41.85 3.87 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 120.409 -0.901 . . . . 0.0 112.34 -179.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG22 ' A' ' 16' ' ' VAL . 41.3 t -132.58 112.93 19.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.093 0.473 . . . . 0.0 110.205 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.686 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -128.04 147.57 50.52 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.43 -179.786 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.8 m -109.67 97.88 7.34 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.703 179.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 69.3 p -98.91 158.35 15.7 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.377 -0.829 . . . . 0.0 111.08 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 36.1 34.77 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.409 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.3 p 74.04 47.0 0.16 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.424 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -161.92 127.19 1.68 Allowed Glycine 0 N--CA 1.452 -0.288 0 N-CA-C 111.466 -0.653 . . . . 0.0 111.466 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.637 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 57.0 m -88.47 126.6 35.32 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 121.476 0.655 . . . . 0.0 111.22 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -146.62 173.74 12.06 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.651 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.953 HG13 ' O ' ' A' ' 6' ' ' GLY . 28.8 t -120.81 121.94 66.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 112.083 0.401 . . . . 0.0 112.083 -179.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.454 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.7 OUTLIER -70.91 -16.4 62.67 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.694 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.799 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.0 m95 64.07 -65.14 0.13 Allowed 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.97 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -53.76 -30.26 43.5 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.319 177.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.769 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.3 mm-40 -73.69 -40.66 63.49 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.905 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.03 -41.78 70.38 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.561 0.696 . . . . 0.0 110.126 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.679 ' O ' HG23 ' A' ' 26' ' ' VAL . 79.7 t80 -57.16 -36.11 70.35 Favored 'General case' 0 CA--C 1.512 -0.49 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.581 179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 23.4 p -70.93 -29.64 65.73 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.583 178.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.04 -47.74 42.24 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.616 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.34 -47.19 91.33 Favored Glycine 0 N--CA 1.451 -0.35 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.244 179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.5 t -58.25 -38.06 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 116.991 0.395 . . . . 0.0 111.499 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.426 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -62.0 -42.09 98.76 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.66 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 7.6 tpm_? -73.72 -42.5 61.1 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.208 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -73.79 -51.15 17.36 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.393 -178.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.87 -1.18 10.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -178.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -82.02 -35.23 29.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.85 0.357 . . . . 0.0 110.922 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -82.48 59.7 4.91 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.551 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.408 ' O ' ' N ' ' A' ' 35' ' ' GLY . . . -99.18 78.55 0.52 Allowed Glycine 0 CA--C 1.517 0.213 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.674 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 66.11 -61.12 0.29 Allowed 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.408 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -148.48 -145.97 4.25 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.678 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER 55.64 80.77 0.13 Allowed 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.75 0.309 . . . . 0.0 110.915 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.274 -0.87 . . . . 0.0 110.896 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.713 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 120.322 0.106 . . . . 0.0 111.251 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.727 ' OH ' ' HA2' ' A' ' 6' ' ' GLY . 1.8 t80 -78.71 133.47 37.16 Favored 'General case' 0 N--CA 1.44 -0.928 0 CA-C-O 120.705 0.288 . . . . 0.0 111.502 179.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.437 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 8.0 m-85 -103.26 41.17 1.29 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.264 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 40.05 24.82 0.07 OUTLIER Glycine 0 C--N 1.335 0.482 0 CA-C-N 115.704 -0.68 . . . . 0.0 113.506 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.42 ' N ' ' O ' ' A' ' 3' ' ' TYR . 2.8 m-20 -148.14 39.69 0.93 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.833 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 56.48 22.8 39.94 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 119.813 -1.184 . . . . 0.0 111.721 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 16' ' ' VAL . 38.6 t -114.79 101.38 12.31 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.43 0 CA-C-O 120.963 0.411 . . . . 0.0 110.746 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.713 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -111.09 161.27 16.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.261 179.36 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 18.8 m -124.31 85.9 2.48 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-O 121.299 0.571 . . . . 0.0 109.831 179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.766 ' O ' ' N ' ' A' ' 12' ' ' SER . 6.8 p -103.97 143.86 32.3 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.158 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 1.8 mmmm 22.55 -61.46 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 114.69 1.367 . . . . 0.0 114.69 178.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.766 ' N ' ' O ' ' A' ' 10' ' ' THR . 59.1 p -81.82 3.49 25.76 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -177.609 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.652 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 114.9 -155.29 16.44 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.94 178.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 61.4 m -92.5 127.52 38.02 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 121.542 0.687 . . . . 0.0 111.52 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.6 p -146.47 170.52 16.68 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.494 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.826 HG22 HG22 ' A' ' 7' ' ' VAL . 15.5 t -118.57 123.21 71.2 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.236 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.466 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -73.96 -13.81 60.94 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.466 0.651 . . . . 0.0 109.306 178.018 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.759 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.8 m95 65.55 -70.49 0.09 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.237 179.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.15 -27.12 30.33 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 119.132 -1.509 . . . . 0.0 110.314 178.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.533 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 0.8 OUTLIER -74.74 -40.73 61.09 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.843 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.833 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.71 -38.41 80.22 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.501 178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.882 ' O ' HG23 ' A' ' 26' ' ' VAL . 17.4 t80 -58.79 -38.26 78.16 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.085 -0.961 . . . . 0.0 108.709 178.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.412 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 22.3 m -70.82 -30.78 67.32 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.173 178.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.08 -48.54 23.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.523 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.838 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -64.35 -38.63 96.1 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.343 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.882 HG23 ' O ' ' A' ' 22' ' ' PHE . 96.0 t -64.38 -39.36 85.26 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 116.906 0.353 . . . . 0.0 110.911 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.486 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.6 OUTLIER -61.53 -40.0 93.08 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.393 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.3 mtp180 -69.18 -47.14 65.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.173 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.838 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 12.8 mt -70.36 -51.45 29.78 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.633 0.73 . . . . 0.0 111.452 -179.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -66.67 -21.05 66.1 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 114.573 -1.194 . . . . 0.0 113.039 -178.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.486 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 21.8 t-20 -83.71 62.26 6.78 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.58 -0.448 . . . . 0.0 110.822 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 150.35 -21.94 1.08 Allowed Glycine 0 C--N 1.331 0.3 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.828 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -153.83 113.96 0.6 Allowed Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.534 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -150.78 102.38 2.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.112 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -119.96 35.32 3.85 Favored Glycine 0 C--N 1.33 0.198 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.207 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -77.61 129.67 35.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.837 0.351 . . . . 0.0 111.107 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 3.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.154 -0.927 . . . . 0.0 110.94 179.582 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.521 ' CD1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -75.86 166.0 24.16 Favored 'General case' 0 N--CA 1.426 -1.632 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 178.118 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.417 ' HD2' HG12 ' A' ' 7' ' ' VAL . 5.7 m-85 -127.81 -20.12 3.95 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.126 -178.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.27 13.77 27.82 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.746 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 -138.44 14.74 2.77 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 122.237 0.215 . . . . 0.0 110.568 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.83 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 92.04 -10.42 74.46 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 119.795 -1.193 . . . . 0.0 111.044 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 16' ' ' VAL . 70.8 t -87.58 107.18 16.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -179.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.596 ' N ' ' CD2' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -120.12 151.0 39.7 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 177.27 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.3 m -113.54 87.59 2.64 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.3 p -91.36 133.91 35.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.679 -178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.6 tttt 77.73 -84.27 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.039 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -153.44 22.68 0.54 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.5 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -152.98 147.05 16.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.163 -1.018 . . . . 0.0 112.885 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 53.6 m -92.31 128.29 38.11 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-O 121.364 0.602 . . . . 0.0 110.731 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.2 m -145.99 152.51 39.5 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.808 -1.087 . . . . 0.0 110.683 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.824 HG22 HG22 ' A' ' 7' ' ' VAL . 11.6 t -99.49 124.83 53.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.989 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.552 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -70.91 -16.89 62.7 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.797 178.136 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.814 ' H ' HG12 ' A' ' 16' ' ' VAL . 84.0 m95 65.9 -60.71 0.28 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.841 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -59.46 -26.26 61.76 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 119.128 -1.511 . . . . 0.0 110.395 177.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.475 ' OE1' ' N ' ' A' ' 20' ' ' GLU . 1.4 mp0 -77.49 -41.74 38.29 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 178.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.83 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.24 -38.76 82.16 Favored 'General case' 0 CA--C 1.514 -0.437 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.01 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.782 ' O ' HG23 ' A' ' 26' ' ' VAL . 66.0 t80 -59.29 -37.05 76.72 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.063 179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.484 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 3.5 t -69.62 -29.75 67.32 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 114.848 -1.069 . . . . 0.0 108.93 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.71 -46.22 47.48 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.663 178.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.67 -45.1 96.49 Favored Glycine 0 N--CA 1.449 -0.5 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.603 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 22' ' ' PHE . 75.0 t -61.06 -38.2 79.05 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 110.81 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.484 ' ND1' ' O ' ' A' ' 23' ' ' SER . 1.0 OUTLIER -61.98 -39.18 91.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.8 tpm_? -73.39 -46.92 46.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.447 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -74.97 -40.93 60.47 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 112.538 0.57 . . . . 0.0 112.538 -178.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -74.26 -18.35 60.74 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -178.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 16.4 t-20 -76.33 82.13 3.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.069 0.461 . . . . 0.0 110.794 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -177.66 -46.65 0.07 OUTLIER Glycine 0 C--N 1.331 0.271 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.28 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.64 4.48 34.64 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.005 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -89.8 -46.96 8.22 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.833 0.317 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 163.46 124.64 0.72 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.516 -0.85 . . . . 0.0 112.893 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 72.29 -155.83 0.09 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 120.48 0.181 . . . . 0.0 111.268 179.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.265 -0.874 . . . . 0.0 110.3 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.586 0.232 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.673 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.3 141.62 35.31 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 120.984 0.421 . . . . 0.0 110.608 -179.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.519 ' HB2' ' O ' ' A' ' 7' ' ' VAL . 4.3 m-85 -102.4 32.0 3.77 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.463 -179.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.51 22.42 0.13 Allowed Glycine 0 C--N 1.337 0.609 0 C-N-CA 121.403 -0.427 . . . . 0.0 112.724 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.421 ' N ' ' O ' ' A' ' 3' ' ' TYR . 16.8 m-80 -148.01 38.94 0.91 Allowed 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.897 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 51.53 46.81 52.89 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.532 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.757 HG22 HG22 ' A' ' 16' ' ' VAL . 53.3 t -142.59 107.52 1.47 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.249 0 CA-C-O 120.812 0.339 . . . . 0.0 111.519 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.673 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -109.51 151.26 26.98 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 178.256 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.678 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -119.39 78.21 1.28 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.499 0.666 . . . . 0.0 109.758 179.869 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.593 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -94.14 135.42 35.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.508 -179.249 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.593 ' HB2' ' O ' ' A' ' 10' ' ' THR . 5.0 mmmt 83.21 -89.68 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.555 179.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 p -149.61 20.79 0.92 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.539 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.16 159.72 29.9 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.743 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.678 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 35.5 m -93.17 132.74 37.04 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.609 0.718 . . . . 0.0 110.926 179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.534 ' N ' ' O ' ' A' ' 8' ' ' HIS . 42.9 m -111.27 -178.46 3.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.999 -179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.049 HG12 ' H ' ' A' ' 18' ' ' TRP . 59.2 t -146.99 137.88 17.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.072 179.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.692 ' O ' ' N ' ' A' ' 19' ' ' GLY . 48.5 t30 -102.45 27.66 6.64 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 1.049 ' H ' HG12 ' A' ' 16' ' ' VAL . 61.2 m95 17.21 -64.93 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 125.202 1.401 . . . . 0.0 113.66 -179.731 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.692 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.84 -33.22 4.87 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 119.636 -1.269 . . . . 0.0 111.35 178.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.43 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -73.87 -44.88 54.04 Favored 'General case' 0 C--O 1.233 0.209 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.171 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.446 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.28 -34.22 74.41 Favored 'General case' 0 CA--C 1.518 -0.283 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.013 178.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.791 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.4 t80 -58.04 -38.31 76.03 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.057 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.0 m -69.01 -31.95 71.14 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.488 178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.32 -45.09 57.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.367 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.628 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -67.9 -38.81 89.4 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.562 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 22' ' ' PHE . 93.1 t -64.08 -39.62 86.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 O-C-N 122.668 -0.313 . . . . 0.0 111.073 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.446 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.9 m-70 -59.88 -48.32 82.16 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -68.87 -43.2 75.86 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.556 179.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.628 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 27.4 mt -70.96 -56.39 6.3 Favored 'General case' 0 CA--C 1.512 -0.481 0 CA-C-O 121.969 0.89 . . . . 0.0 112.198 -179.026 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -64.85 -15.36 61.76 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.872 -1.513 . . . . 0.0 113.218 -177.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.446 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 16.4 t30 -84.52 -36.56 22.11 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.935 179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 48.8 97.86 0.01 OUTLIER Glycine 0 CA--C 1.519 0.341 0 C-N-CA 121.034 -0.603 . . . . 0.0 113.061 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . 96.71 149.18 25.23 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.166 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -82.38 69.26 9.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.095 0.474 . . . . 0.0 110.21 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.8 -36.88 24.38 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.06 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 77.42 112.22 0.07 Allowed 'General case' 0 N--CA 1.464 0.275 0 CA-C-O 120.67 0.272 . . . . 0.0 110.696 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.688 179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.784 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 1.1 ttmt . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 111.199 0.074 . . . . 0.0 111.199 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.733 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.15 139.93 36.59 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.237 179.414 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 5' ' ' ASN . 9.9 m-85 -105.48 35.47 2.84 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.839 -179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.32 23.93 0.11 Allowed Glycine 0 C--N 1.336 0.561 0 CA-C-N 116.252 -0.431 . . . . 0.0 113.085 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.424 ' N ' ' O ' ' A' ' 3' ' ' TYR . 1.6 m120 -146.98 33.25 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.962 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 57.57 48.74 79.09 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.632 -178.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.796 HG22 HG22 ' A' ' 16' ' ' VAL . 15.6 t -149.12 109.61 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.997 0.427 . . . . 0.0 111.283 -179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.784 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -120.44 151.25 39.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.059 179.076 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 6.4 m -127.21 92.07 3.45 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.52 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.5 p -96.17 118.25 32.37 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.665 -178.415 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.52 ' HB2' ' O ' ' A' ' 10' ' ' THR . 2.1 mmmp? 87.57 -85.38 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.505 179.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 66.0 p -150.49 31.89 0.65 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.478 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -159.89 143.91 9.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.002 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 62.0 m -97.59 139.55 33.33 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.573 0.702 . . . . 0.0 111.726 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 p -125.7 171.62 10.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.712 -1.131 . . . . 0.0 110.065 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.962 HG13 ' O ' ' A' ' 6' ' ' GLY . 43.0 t -136.33 136.79 48.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.904 0.383 . . . . 0.0 111.635 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 19' ' ' GLY . 44.8 t30 -99.31 27.11 5.4 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.911 ' H ' HG12 ' A' ' 16' ' ' VAL . 80.3 m95 19.51 -69.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.393 -1.276 . . . . 0.0 113.794 -179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.638 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -45.31 -31.38 3.26 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 119.62 -1.276 . . . . 0.0 111.496 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.31 -44.11 47.21 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.0 -34.78 73.76 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.835 178.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 26.4 t80 -58.84 -38.11 77.97 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 178.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.1 t -68.18 -31.28 70.72 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.852 178.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.28 -48.65 22.25 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.728 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.0 -34.65 87.66 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.531 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.4 t -66.01 -40.06 86.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 CA-C-N 116.84 0.32 . . . . 0.0 110.271 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.501 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.9 m-70 -62.84 -54.49 38.02 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -62.99 -36.34 83.19 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.653 179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.665 ' C ' HD13 ' A' ' 29' ' ' LEU . 2.0 tm? -72.36 -61.29 1.85 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.75 0.786 . . . . 0.0 111.338 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.611 ' N ' HD13 ' A' ' 29' ' ' LEU . . . -67.04 -22.63 65.86 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.455 -1.248 . . . . 0.0 113.38 -177.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.501 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.5 t30 -80.79 68.85 7.18 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.542 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.7 96.94 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.854 -0.688 . . . . 0.0 112.251 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 110.09 118.42 3.97 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.762 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -150.93 -46.86 0.12 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.841 0.353 . . . . 0.0 110.662 179.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 86.08 140.66 5.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.714 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -162.21 35.43 0.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.85 0.357 . . . . 0.0 110.549 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 4.2 m-90 . . . . . 0 C--O 1.249 1.029 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.908 -179.983 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.74 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 16.8 ptpt . . . . . 0 N--CA 1.485 1.31 0 CA-C-O 120.441 0.162 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.724 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -85.09 142.11 29.77 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.112 179.25 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.464 ' N ' ' O ' ' A' ' 7' ' ' VAL . 29.3 m-85 -105.77 42.2 1.28 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.665 -0.243 . . . . 0.0 111.424 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 41.57 25.25 0.17 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.333 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.47 29.66 1.03 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.67 0.272 . . . . 0.0 110.622 -179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.684 ' O ' ' HA ' ' A' ' 16' ' ' VAL . . . 77.05 -12.24 12.67 Favored Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.22 -0.99 . . . . 0.0 112.535 -178.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.741 HG22 ' HB ' ' A' ' 16' ' ' VAL . 40.4 t -90.68 129.29 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.74 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.1 OUTLIER -139.7 127.15 21.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.388 178.382 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.3 OUTLIER -106.44 89.35 3.01 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-O 121.421 0.629 . . . . 0.0 110.004 179.139 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.581 ' OG1' ' N ' ' A' ' 11' ' ' LYS . 0.2 OUTLIER -96.89 -167.53 1.56 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.14 -0.936 . . . . 0.0 111.274 -179.164 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' N ' ' OG1' ' A' ' 10' ' ' THR . 0.0 OUTLIER -56.47 -21.22 24.19 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.454 -178.91 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 91.1 p -94.04 16.6 14.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.366 178.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 90.6 -155.94 24.4 Favored Glycine 0 C--N 1.333 0.403 0 C-N-CA 121.018 -0.61 . . . . 0.0 111.729 -179.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 45.7 m -90.86 131.1 36.7 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 178.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.43 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 0.9 OUTLIER -150.21 110.94 4.28 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.121 0.486 . . . . 0.0 111.503 -179.35 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.756 HG13 ' NE1' ' A' ' 18' ' ' TRP . 1.6 p -96.59 115.12 35.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.39 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.616 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 21.0 t-20 -52.47 -26.14 12.07 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.386 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.756 ' NE1' HG13 ' A' ' 16' ' ' VAL . 75.4 m95 70.17 -59.47 0.51 Allowed 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.616 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.7 -27.12 26.73 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 119.291 -1.433 . . . . 0.0 109.855 176.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.616 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.1 OUTLIER -74.69 -43.73 53.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.12 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -71.59 -35.51 70.56 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.777 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.85 ' O ' HG23 ' A' ' 26' ' ' VAL . 14.7 t80 -59.66 -36.43 76.41 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 178.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.437 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -68.31 -31.51 70.98 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.464 178.229 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.61 -48.92 20.14 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.619 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.2 -34.6 90.4 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.079 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.6 t -67.6 -39.37 82.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.316 0 CA-C-O 120.651 0.262 . . . . 0.0 110.594 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.453 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 4.3 m-70 -62.87 -51.47 66.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.5 mtm180 -67.42 -38.41 84.56 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.0 tp -73.19 -49.01 30.39 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.296 0.569 . . . . 0.0 112.199 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.443 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.83 -29.96 66.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.093 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.6 t-20 -81.24 59.39 3.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.051 0.453 . . . . 0.0 110.767 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -98.67 72.48 0.57 Allowed Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.329 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 173.02 -37.99 0.14 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.081 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -87.73 -49.96 6.79 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.953 0.406 . . . . 0.0 110.346 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -84.49 -150.52 11.74 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.835 -0.697 . . . . 0.0 112.22 179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 36' ' ' PHE . 27.7 p90 -76.95 134.95 38.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.991 0.424 . . . . 0.0 110.99 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.615 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 111.568 0.21 . . . . 0.0 111.568 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.695 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -79.55 136.25 36.82 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.252 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 12.5 m-85 -97.59 -31.81 12.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 111.367 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.54 -26.49 3.18 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.866 179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -107.55 50.71 0.76 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.701 ' HA3' ' HB2' ' A' ' 21' ' ' ALA . . . 51.0 26.43 11.46 Favored Glycine 0 N--CA 1.447 -0.601 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.065 -178.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 16' ' ' VAL . 40.5 t -109.28 109.09 27.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.455 0.169 . . . . 0.0 111.25 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.615 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -112.49 145.04 40.95 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.229 0.537 . . . . 0.0 110.373 178.432 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.696 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -114.16 79.21 1.23 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 178.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.0 OUTLIER -92.99 133.65 35.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.889 -1.051 . . . . 0.0 111.939 -178.268 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.478 ' HB2' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 83.05 -87.26 0.02 OUTLIER 'General case' 0 C--O 1.231 0.116 0 CA-C-N 114.779 -1.1 . . . . 0.0 111.242 179.335 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.92 22.63 0.77 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.403 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -157.26 153.52 24.74 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.438 -0.887 . . . . 0.0 112.609 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.696 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 79.1 m -94.08 136.41 34.39 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-O 121.351 0.596 . . . . 0.0 110.742 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.3 168.37 19.94 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.361 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.823 HG22 HG22 ' A' ' 7' ' ' VAL . 38.7 t -125.92 119.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.566 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.528 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 1.6 t-20 -65.26 -18.18 65.1 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.795 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.0 m95 64.94 -63.25 0.18 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.126 179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -58.3 -29.94 63.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 119.154 -1.498 . . . . 0.0 110.275 177.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.695 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 4.3 mt-10 -75.33 -40.56 58.25 Favored 'General case' 0 C--O 1.232 0.177 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 177.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.701 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.49 -37.28 74.2 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.865 178.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.918 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.3 t80 -59.5 -36.99 77.11 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 115.19 -0.914 . . . . 0.0 108.696 178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.478 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 16.7 t -66.43 -31.28 71.93 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.097 177.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 21' ' ' ALA . . . -73.92 -48.46 30.57 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.953 179.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.81 -34.14 87.69 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.041 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.5 t -68.4 -37.01 77.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.693 0.282 . . . . 0.0 111.009 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' A' ' 23' ' ' SER . 3.4 m-70 -61.6 -41.82 97.98 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.87 -43.7 57.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.224 179.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 16.8 tp -71.58 -46.37 59.55 Favored 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.894 -179.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -73.16 0.99 10.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.535 -178.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -80.18 -27.64 38.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.794 0.33 . . . . 0.0 110.79 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.64 -92.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.496 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -179.74 76.04 0.06 OUTLIER Glycine 0 C--N 1.329 0.176 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.445 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 -152.22 46.15 0.74 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.354 . . . . 0.0 110.927 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.26 21.47 1.38 Allowed Glycine 0 CA--C 1.518 0.229 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.597 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -79.28 175.1 10.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.791 0.329 . . . . 0.0 110.856 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 7.5 t90 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.248 -0.882 . . . . 0.0 111.278 179.608 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.702 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.355 0.121 . . . . 0.0 111.092 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.78 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 1.2 t80 -77.79 135.78 38.03 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 120.888 0.375 . . . . 0.0 111.167 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.476 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 20.2 m-85 -106.06 40.53 1.57 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.33 179.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 44.76 20.55 0.23 Allowed Glycine 0 CA--C 1.521 0.459 0 CA-C-N 115.949 -0.569 . . . . 0.0 113.328 -179.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -147.91 48.17 1.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.781 0.324 . . . . 0.0 110.629 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.694 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 49.89 27.4 9.8 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.029 -1.081 . . . . 0.0 112.037 -179.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 16' ' ' VAL . 36.2 t -118.36 105.99 18.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.787 0.327 . . . . 0.0 110.931 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.702 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -109.33 149.09 29.99 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.379 179.43 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.799 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -113.23 65.24 0.65 Allowed 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.933 0.873 . . . . 0.0 110.036 179.166 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.459 ' O ' ' O ' ' A' ' 11' ' ' LYS . 1.4 t -119.15 173.96 6.61 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.059 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.459 ' O ' ' O ' ' A' ' 10' ' ' THR . 0.1 OUTLIER 29.11 101.32 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.236 0 O-C-N 123.734 0.646 . . . . 0.0 112.375 -179.355 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER 82.02 -46.48 0.19 Allowed 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.029 179.986 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 170.03 -134.59 3.21 Favored Glycine 0 C--N 1.332 0.312 0 C-N-CA 119.995 -1.098 . . . . 0.0 113.295 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.799 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 30.7 m -91.6 130.46 37.41 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 121.451 0.643 . . . . 0.0 111.099 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 79.8 p -143.48 174.63 10.59 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.328 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 7' ' ' VAL . 45.3 t -131.83 122.13 48.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.214 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.482 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -70.75 -14.2 62.35 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 178.314 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.824 ' H ' HG12 ' A' ' 16' ' ' VAL . 81.6 m95 62.41 -63.43 0.1 Allowed 'General case' 0 CA--C 1.515 -0.399 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.273 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -55.84 -28.75 53.45 Favored Glycine 0 N--CA 1.444 -0.805 0 C-N-CA 119.074 -1.536 . . . . 0.0 110.654 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.78 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -74.31 -41.46 61.11 Favored 'General case' 0 C--O 1.233 0.206 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.599 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.61 -35.05 72.78 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.982 178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.873 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.3 t80 -59.18 -36.76 75.89 Favored 'General case' 0 CA--C 1.514 -0.414 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.416 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 3.9 t -67.11 -33.09 74.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.205 178.303 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.1 -46.06 53.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.233 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.99 -32.09 81.51 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.325 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.873 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -68.39 -36.78 76.32 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.225 0 CA-C-O 120.738 0.304 . . . . 0.0 110.314 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.416 ' CE1' ' O ' ' A' ' 23' ' ' SER . 1.9 m-70 -61.42 -48.67 80.15 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -69.09 -41.79 77.03 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.223 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.9 tp -71.3 -45.01 64.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.976 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 26' ' ' VAL . . . -71.94 -32.91 67.79 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.418 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 9.4 t-20 -82.66 -23.46 34.2 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.766 0.317 . . . . 0.0 111.064 -179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -149.84 -111.35 0.56 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.319 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.84 -66.21 0.65 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.7 m-20 -150.3 91.62 1.78 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.865 0.364 . . . . 0.0 110.811 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.443 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -61.49 -152.23 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.399 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.443 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 97.6 m-85 -161.0 154.11 21.39 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.774 0.321 . . . . 0.0 110.666 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.88 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.681 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.6 OUTLIER . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.314 0.102 . . . . 0.0 111.196 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.732 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -79.85 139.88 37.0 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.7 179.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -108.31 35.87 3.01 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.082 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.74 20.39 0.41 Allowed Glycine 0 C--N 1.334 0.446 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.756 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -146.48 45.95 1.21 Allowed 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.865 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 44.63 51.27 8.07 Favored Glycine 0 C--O 1.226 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.209 -178.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 16' ' ' VAL . 40.6 t -145.15 109.43 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.96 0.41 . . . . 0.0 110.599 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.732 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -123.0 138.98 54.55 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.478 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.683 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.8 m -109.14 97.83 7.37 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.552 179.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 44.1 p -95.14 -166.44 1.46 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.007 -178.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.9 -17.39 23.78 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.252 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -95.87 2.84 53.91 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.113 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.554 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 106.09 -157.7 15.89 Favored Glycine 0 C--N 1.333 0.382 0 C-N-CA 121.062 -0.59 . . . . 0.0 111.627 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.683 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 74.7 m -90.85 132.3 35.98 Favored 'General case' 0 CA--C 1.512 -0.482 0 CA-C-O 121.324 0.583 . . . . 0.0 110.534 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.81 176.25 8.86 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.965 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 7' ' ' VAL . 90.5 t -138.8 125.34 24.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.918 -179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.415 ' O ' ' N ' ' A' ' 19' ' ' GLY . 0.7 OUTLIER -69.35 -22.35 63.76 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.988 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.728 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.6 m95 66.31 -64.94 0.2 Allowed 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.709 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 17' ' ' ASN . . . -56.31 -28.24 54.54 Favored Glycine 0 N--CA 1.443 -0.878 0 C-N-CA 119.065 -1.54 . . . . 0.0 110.58 177.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.555 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 40.4 mt-10 -75.85 -41.16 53.23 Favored 'General case' 0 CA--C 1.521 -0.158 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.525 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.18 -36.64 72.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.631 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.5 t80 -59.27 -38.04 79.15 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.746 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 t -68.31 -30.08 68.98 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.537 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.23 -48.75 21.92 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.099 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.738 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.09 -37.06 94.32 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.218 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.5 t -64.53 -40.01 87.57 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 CA-C-N 116.802 0.301 . . . . 0.0 110.505 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -59.98 -32.3 70.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -75.52 -53.46 8.6 Favored 'General case' 0 CA--C 1.534 0.356 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.347 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.738 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 3.6 mt -71.67 -48.07 49.95 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.393 0.616 . . . . 0.0 112.306 -178.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -66.07 -5.06 8.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.992 -1.003 . . . . 0.0 112.966 -177.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -83.01 -23.27 33.35 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.915 -0.314 . . . . 0.0 110.849 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -71.06 -79.79 0.36 Allowed Glycine 0 C--N 1.331 0.258 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.599 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 158.3 111.57 0.31 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.546 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -90.4 -27.13 19.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.789 0.328 . . . . 0.0 111.191 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.95 -117.73 5.67 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.355 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -163.12 45.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.783 0.325 . . . . 0.0 111.108 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 5.5 t90 . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.258 -0.877 . . . . 0.0 110.923 179.638 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.62 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 10.7 ptmt . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 120.458 0.171 . . . . 0.0 111.153 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -81.64 139.6 34.88 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.615 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 5' ' ' ASN . 12.6 m-85 -105.47 35.48 2.84 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.058 -179.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.11 22.94 0.2 Allowed Glycine 0 CA--C 1.521 0.453 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.764 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.404 ' N ' ' O ' ' A' ' 3' ' ' TYR . 54.2 m-20 -146.48 33.57 0.96 Allowed 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.907 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.24 51.92 50.91 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.201 -0.999 . . . . 0.0 111.797 -178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 16' ' ' VAL . 24.8 t -147.89 105.8 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.946 0.403 . . . . 0.0 110.7 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -115.67 156.36 26.04 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.299 179.569 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 4.4 m -128.21 81.13 2.0 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.423 0.63 . . . . 0.0 109.306 179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 1.3 p -96.54 127.4 42.5 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.745 -178.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 10' ' ' THR . 1.2 mmpt? 92.42 -85.88 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 114.854 -1.066 . . . . 0.0 111.41 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 96.4 p -151.44 26.5 0.68 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.677 -179.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -167.45 158.47 31.38 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.572 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 59.1 m -96.3 140.37 31.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.548 0.689 . . . . 0.0 111.692 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -131.2 174.3 10.18 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.661 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.922 HG22 HG22 ' A' ' 7' ' ' VAL . 66.1 t -136.31 128.96 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.801 0.334 . . . . 0.0 111.706 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -73.22 -22.37 60.45 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.711 ' H ' HG12 ' A' ' 16' ' ' VAL . 89.1 m95 68.26 -63.92 0.32 Allowed 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.557 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.28 -30.7 64.79 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.414 178.178 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -74.27 -40.96 61.98 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.487 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -71.87 -33.3 68.28 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.902 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.833 ' O ' HG23 ' A' ' 26' ' ' VAL . 28.7 t80 -60.35 -38.05 82.58 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.425 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 24.7 p -69.75 -31.4 69.35 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.886 -1.052 . . . . 0.0 109.731 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.64 -47.98 28.95 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.326 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.702 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -65.7 -37.86 93.94 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.582 -0.735 . . . . 0.0 112.493 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 22' ' ' PHE . 81.5 t -64.06 -39.69 86.38 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 117.061 0.43 . . . . 0.0 110.229 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.526 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 2.4 m-70 -61.66 -37.63 84.76 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -71.02 -49.48 44.61 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.154 179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.702 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 21.9 mt -69.59 -50.39 45.0 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-O 121.722 0.773 . . . . 0.0 111.975 -179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -64.75 -28.04 69.31 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.401 -1.272 . . . . 0.0 113.14 -177.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.1 OUTLIER -83.85 -23.08 31.48 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.654 179.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.63 110.87 2.45 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.58 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 175.79 125.88 0.91 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.544 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.1 m-20 -87.03 -24.18 24.72 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.712 0.291 . . . . 0.0 111.002 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.02 25.58 2.25 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.807 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 76.59 -1.11 2.93 Favored 'General case' 0 CA--C 1.531 0.222 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 2.8 m0 . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.185 -0.912 . . . . 0.0 110.887 179.919 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.863 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 2.1 ttpt . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 111.406 0.15 . . . . 0.0 111.406 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.652 ' OH ' ' HB3' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -78.62 138.37 38.3 Favored 'General case' 0 N--CA 1.446 -0.656 0 CA-C-O 120.887 0.375 . . . . 0.0 110.804 179.227 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.41 ' HB2' ' HB ' ' A' ' 7' ' ' VAL . 6.4 m-85 -105.41 39.07 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 45.59 17.45 0.16 Allowed Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.368 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.401 ' N ' ' O ' ' A' ' 3' ' ' TYR . 0.5 OUTLIER -148.89 48.14 1.0 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.829 0.314 . . . . 0.0 110.686 -179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 1.013 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 46.67 52.02 11.87 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 119.742 -1.218 . . . . 0.0 111.407 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.827 HG22 HG22 ' A' ' 16' ' ' VAL . 25.1 t -146.48 99.98 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.863 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -108.4 150.52 27.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.4 0.619 . . . . 0.0 110.996 179.801 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.2 OUTLIER -115.65 93.83 4.44 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 178.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.578 ' O ' ' N ' ' A' ' 12' ' ' SER . 44.7 p -93.89 148.16 22.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.986 -177.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.496 ' HG3' ' N ' ' A' ' 12' ' ' SER . 19.1 pttt 47.08 -66.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 114.408 -1.269 . . . . 0.0 113.387 -179.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.578 ' N ' ' O ' ' A' ' 10' ' ' THR . 29.0 t -154.59 17.08 0.46 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -152.96 150.26 22.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 119.768 -1.206 . . . . 0.0 113.372 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.684 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.0 m -93.1 133.89 35.81 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 109.998 179.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.436 ' OG ' ' N ' ' A' ' 16' ' ' VAL . 4.7 t -140.74 178.42 7.35 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.003 -179.251 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.013 HG13 ' O ' ' A' ' 6' ' ' GLY . 39.0 t -133.12 114.57 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.857 -179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB3' ' OE1' ' A' ' 20' ' ' GLU . 1.2 m-20 -65.16 -17.03 64.14 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.677 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.5 m95 66.24 -69.58 0.11 Allowed 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.558 179.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.6 -28.08 20.81 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 118.947 -1.597 . . . . 0.0 110.459 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.652 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 5.6 mp0 -76.03 -40.7 52.93 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 177.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.775 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.04 -37.21 75.51 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.866 178.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 26' ' ' VAL . 24.4 t80 -59.6 -37.66 79.14 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.614 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.442 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 28.9 t -66.83 -31.04 71.39 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.144 177.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.32 -48.62 27.1 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.187 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.63 -34.96 91.11 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.092 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 22' ' ' PHE . 97.6 t -64.81 -40.64 89.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 O-C-N 122.757 -0.261 . . . . 0.0 110.667 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.447 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 5.8 m-70 -61.25 -37.62 83.77 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.2 tpm_? -73.13 -46.97 48.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.851 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 22.1 mt -70.95 -57.61 4.4 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.834 0.826 . . . . 0.0 112.294 -179.148 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -65.98 -4.24 6.74 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 114.075 -1.42 . . . . 0.0 113.519 -177.432 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 34.7 t30 -83.25 67.46 9.23 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.461 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -152.15 -81.73 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.572 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -82.1 -137.73 2.6 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.687 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.1 p-10 -153.63 118.93 5.15 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.867 0.365 . . . . 0.0 110.962 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 78.28 148.62 3.83 Favored Glycine 0 CA--C 1.517 0.17 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.634 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -78.35 -45.64 22.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.304 . . . . 0.0 111.084 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 75.3 m95 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.19 -0.909 . . . . 0.0 110.896 179.874 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.429 0 N-CA-C 111.298 0.11 . . . . 0.0 111.298 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.697 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -81.71 145.43 30.52 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.049 179.42 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -107.93 32.92 4.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.609 -179.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.09 18.97 0.51 Allowed Glycine 0 CA--C 1.522 0.516 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.75 -179.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -148.11 47.48 1.07 Allowed 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.862 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 43.39 49.62 6.83 Favored Glycine 0 C--N 1.333 0.375 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.329 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.763 HG22 HG22 ' A' ' 16' ' ' VAL . 41.2 t -147.59 111.61 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.879 0.371 . . . . 0.0 111.192 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.697 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -123.39 128.37 49.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.6 179.351 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.688 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.5 OUTLIER -105.07 97.02 6.93 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.754 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.8 p -91.96 -169.97 2.42 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.832 -178.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.44 ' HD3' ' N ' ' A' ' 11' ' ' LYS . 0.1 OUTLIER -60.03 -17.5 39.48 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.471 -179.426 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 p -93.25 -21.98 19.28 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.895 0.379 . . . . 0.0 110.669 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 137.64 -161.19 25.37 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 121.126 -0.559 . . . . 0.0 111.936 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.688 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 90.9 m -90.43 134.98 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.071 0.462 . . . . 0.0 110.219 179.294 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.2 m -135.27 171.3 14.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.424 -179.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.862 HG13 ' O ' ' A' ' 6' ' ' GLY . 48.4 t -140.34 123.4 16.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.72 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.568 ' HB3' ' HB2' ' A' ' 20' ' ' GLU . 0.8 OUTLIER -69.29 -19.81 63.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.408 0.623 . . . . 0.0 109.394 178.192 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.737 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.1 m95 66.96 -62.61 0.3 Allowed 'General case' 0 CA--C 1.514 -0.416 0 CA-C-N 115.027 -0.988 . . . . 0.0 111.784 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.06 -31.65 61.95 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.784 178.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.568 ' HB2' ' HB3' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -76.14 -43.39 43.24 Favored 'General case' 0 C--O 1.232 0.144 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.366 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.552 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.91 -39.15 76.34 Favored 'General case' 0 CA--C 1.515 -0.396 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.965 178.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 26' ' ' VAL . 64.7 t80 -58.41 -37.04 74.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.257 179.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.448 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 24.1 p -69.88 -29.25 66.42 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.844 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -74.66 -46.6 36.97 Favored 'General case' 0 N--CA 1.456 -0.164 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.731 178.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.83 -47.02 93.02 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.63 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 22' ' ' PHE . 86.0 t -58.92 -42.96 87.48 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-O 120.677 0.275 . . . . 0.0 111.133 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.637 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -58.02 -34.19 69.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.108 0.48 . . . . 0.0 110.112 -179.778 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 41.3 mtp180 -83.6 -43.3 15.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.088 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 20.7 tp -74.69 -56.04 5.23 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 113.139 0.792 . . . . 0.0 113.139 -178.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.7 -26.4 65.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 112.735 0.643 . . . . 0.0 112.735 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.637 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 1.1 t-20 -84.07 -43.07 15.45 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.168 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 49.81 72.23 0.51 Allowed Glycine 0 C--N 1.33 0.248 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 -179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.72 -141.65 2.95 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.559 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 49.0 m-20 -98.14 -68.43 0.8 Allowed 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.06 122.92 6.08 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.603 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -78.17 56.76 1.71 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.747 0.308 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.2 t-105 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.232 -0.89 . . . . 0.0 110.691 179.575 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.3 tttm . . . . . 0 N--CA 1.485 1.309 0 N-CA-C 111.319 0.118 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.772 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -89.35 173.27 8.47 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 176.633 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 9.6 m-85 -132.55 -31.71 1.36 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.651 -0.419 . . . . 0.0 111.734 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 135.62 -35.76 2.12 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.454 179.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -101.34 49.97 0.86 Allowed 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.574 ' HA2' ' CE2' ' A' ' 2' ' ' TYR . . . 53.3 20.83 10.9 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.11 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.699 HG22 HG22 ' A' ' 16' ' ' VAL . 40.0 t -104.3 125.13 59.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.415 0.524 . . . . 0.0 112.415 -179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.772 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -138.66 132.16 30.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.293 177.862 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 35.4 m -105.09 104.21 13.9 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 178.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 30.2 p -97.23 -168.48 1.7 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.328 -178.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 4.2 pttm -61.24 -16.69 47.92 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.551 -179.3 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.42 -25.79 19.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.417 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 140.62 -160.57 26.55 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.619 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.647 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 75.1 m -92.29 128.63 38.2 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.202 0.525 . . . . 0.0 110.322 179.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 49.4 m -136.74 -177.9 4.94 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.84 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.787 HG12 ' H ' ' A' ' 18' ' ' TRP . 47.7 t -140.96 129.7 24.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.986 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -69.36 -22.45 63.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.223 0.535 . . . . 0.0 109.771 178.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.787 ' H ' HG12 ' A' ' 16' ' ' VAL . 88.0 m95 68.63 -60.82 0.43 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 115.155 -0.929 . . . . 0.0 111.881 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -59.67 -27.71 64.32 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 118.884 -1.627 . . . . 0.0 110.675 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -76.5 -42.56 42.94 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.235 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -70.07 -34.98 73.86 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.728 178.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.931 ' O ' HG23 ' A' ' 26' ' ' VAL . 29.3 t80 -60.43 -37.6 81.4 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 178.102 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' CE1' ' A' ' 27' ' ' HIS . 0.4 OUTLIER -67.5 -30.2 69.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.608 -1.178 . . . . 0.0 109.637 178.42 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.14 -47.98 22.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.064 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.83 92.54 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.039 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 22' ' ' PHE . 92.8 t -66.68 -38.19 81.06 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.218 0 CA-C-O 120.659 0.266 . . . . 0.0 110.596 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.421 ' CE1' ' O ' ' A' ' 23' ' ' SER . 2.3 m-70 -62.02 -43.37 98.99 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.506 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 40.5 mtp180 -72.63 -44.47 61.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.275 178.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 22.0 tp -70.56 -44.34 67.62 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.877 -178.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.452 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -72.82 -7.62 51.6 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.441 -178.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.2 t30 -82.02 -24.18 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.773 0.32 . . . . 0.0 110.933 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.63 36.82 2.73 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.382 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 69.19 115.84 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.568 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 19.1 p-10 -89.28 -24.32 22.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.844 0.354 . . . . 0.0 110.733 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.04 150.68 13.39 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.091 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -161.69 117.59 2.08 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.794 0.331 . . . . 0.0 110.928 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 28.7 p90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.956 -179.975 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.571 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 120.481 0.181 . . . . 0.0 111.325 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.718 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.2 OUTLIER -83.37 145.09 29.22 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.912 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -109.64 34.83 3.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.755 0.312 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 47.39 17.6 0.44 Allowed Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.687 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.521 ' O ' HG23 ' A' ' 7' ' ' VAL . 29.6 m-20 -146.36 49.21 1.18 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.925 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 39.9 53.41 3.15 Favored Glycine 0 C--O 1.224 -0.487 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.278 -178.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.905 HG22 HG22 ' A' ' 16' ' ' VAL . 42.4 t -145.29 107.54 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.779 0.323 . . . . 0.0 110.753 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.718 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -115.24 135.09 54.54 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.6 179.229 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.99 75.97 1.07 Allowed 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.554 0.692 . . . . 0.0 109.29 179.245 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB2' ' A' ' 11' ' ' LYS . 4.1 p -95.69 137.28 34.98 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.797 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 10' ' ' THR . 9.8 mttt 85.59 -87.96 0.01 OUTLIER 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.914 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.06 21.8 0.67 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.965 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -160.17 161.83 32.77 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.233 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 93.3 m -94.51 140.94 29.18 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.479 0.656 . . . . 0.0 110.928 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.9 p -133.45 167.29 20.71 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.233 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.925 HG13 ' O ' ' A' ' 6' ' ' GLY . 63.6 t -135.09 120.57 30.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.802 -179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -63.47 -24.33 67.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.412 0.625 . . . . 0.0 109.425 178.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.678 ' H ' HG12 ' A' ' 16' ' ' VAL . 87.2 m95 68.16 -62.54 0.36 Allowed 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.293 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.85 -30.23 56.41 Favored Glycine 0 N--CA 1.448 -0.527 0 C-N-CA 119.116 -1.516 . . . . 0.0 110.787 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.443 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.4 OUTLIER -75.52 -44.28 44.5 Favored 'General case' 0 C--O 1.232 0.169 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 178.301 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.531 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.79 -40.76 75.79 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.604 178.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.621 ' O ' HG23 ' A' ' 26' ' ' VAL . 39.8 t80 -59.59 -40.07 86.23 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.064 179.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.462 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 69.7 m -70.21 -28.25 65.14 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.74 -1.118 . . . . 0.0 109.7 178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.19 -53.21 8.6 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.319 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.6 -42.35 97.73 Favored Glycine 0 N--CA 1.45 -0.368 0 CA-C-N 115.44 -0.8 . . . . 0.0 112.335 179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 22' ' ' PHE . 77.1 t -64.77 -41.86 93.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 116.793 0.296 . . . . 0.0 111.563 -179.708 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.51 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -60.6 -42.44 96.8 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.082 -0.647 . . . . 0.0 109.283 179.695 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.409 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 0.7 OUTLIER -72.59 -45.01 61.25 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.515 179.082 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.465 ' CD2' ' HA ' ' A' ' 26' ' ' VAL . 0.4 OUTLIER -70.91 -46.2 62.95 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.073 0.463 . . . . 0.0 111.446 -179.153 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.45 ' N ' ' HG ' ' A' ' 29' ' ' LEU . . . -79.31 -78.66 0.15 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.446 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.51 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 8.8 t30 43.96 71.6 0.24 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 121.11 0.481 . . . . 0.0 110.707 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 148.3 -79.47 0.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.624 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 52.5 45.5 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.123 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 m120 -150.6 92.41 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.799 0.333 . . . . 0.0 110.569 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 118.79 2.5 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.945 -179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -161.94 33.61 0.12 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.823 0.344 . . . . 0.0 110.674 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 1.8 m95 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.16 -0.924 . . . . 0.0 110.863 179.823 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.808 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.1 ptpp? . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.486 0.184 . . . . 0.0 111.046 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.657 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -83.2 134.53 34.96 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.75 -179.911 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -106.09 39.2 1.84 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.136 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.56 23.13 0.29 Allowed Glycine 0 C--N 1.336 0.556 0 C-N-CA 121.198 -0.525 . . . . 0.0 113.43 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 9.7 m-20 -145.54 40.83 1.21 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.433 ' HA2' ' OH ' ' A' ' 2' ' ' TYR . . . 57.37 13.29 10.28 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.612 -178.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 16' ' ' VAL . 39.8 t -103.67 119.99 53.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-O 120.869 0.366 . . . . 0.0 111.212 179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.808 ' HA ' ' O ' ' A' ' 1' ' ' LYS . 0.0 OUTLIER -132.5 138.99 47.74 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.342 178.648 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.666 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 26.3 m -108.15 103.29 12.45 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 51.2 p -95.35 -168.14 1.74 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.113 -178.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.17 -16.95 37.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.597 -179.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -91.97 -29.12 16.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.977 0.418 . . . . 0.0 110.481 179.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.505 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 143.97 -161.64 27.82 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 121.035 -0.603 . . . . 0.0 111.737 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.666 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 78.1 m -90.39 126.48 35.89 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.391 0.615 . . . . 0.0 110.752 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.53 172.46 12.68 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.87 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.903 HG22 HG22 ' A' ' 7' ' ' VAL . 42.2 t -128.98 124.98 62.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.414 ' HB2' ' OE1' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -69.76 -17.95 63.47 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.152 0.501 . . . . 0.0 109.692 178.592 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.817 ' H ' HG12 ' A' ' 16' ' ' VAL . 86.7 m95 65.47 -64.85 0.18 Allowed 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.322 -0.854 . . . . 0.0 111.726 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.66 -25.36 43.09 Favored Glycine 0 N--CA 1.445 -0.754 0 C-N-CA 118.812 -1.661 . . . . 0.0 110.912 178.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.552 ' HB3' ' OH ' ' A' ' 2' ' ' TYR . 3.4 mt-10 -77.8 -43.8 29.48 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.017 -0.735 . . . . 0.0 109.017 178.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.419 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -68.87 -37.09 78.84 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.792 178.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.794 ' O ' HG23 ' A' ' 26' ' ' VAL . 20.8 t80 -60.14 -38.92 84.56 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.451 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 1.0 OUTLIER -71.16 -29.92 65.81 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.143 178.568 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.15 -48.48 23.47 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.849 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -63.86 -41.15 98.88 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.391 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 22' ' ' PHE . 84.0 t -64.47 -39.72 86.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.849 0.325 . . . . 0.0 111.181 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -61.47 -35.83 78.73 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.1 mtt180 -74.81 -47.68 29.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.242 178.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 10.7 mt -72.11 -53.06 13.94 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-O 121.605 0.717 . . . . 0.0 112.289 -179.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -67.54 -12.0 59.33 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.439 -177.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 63.4 t-20 -85.51 -39.74 17.12 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.543 -0.463 . . . . 0.0 111.157 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.6 -72.15 2.36 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.457 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 115.08 27.97 3.01 Favored Glycine 0 CA--C 1.518 0.254 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.738 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -91.63 87.4 6.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.9 0.381 . . . . 0.0 110.977 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 110.88 -175.57 18.0 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.505 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 47.88 57.01 6.44 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.892 0.377 . . . . 0.0 111.142 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.888 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.575 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.363 0.125 . . . . 0.0 111.29 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.739 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -79.6 138.41 37.43 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.38 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -102.09 34.16 2.81 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.469 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.32 24.47 0.21 Allowed Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.944 -0.571 . . . . 0.0 112.981 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -147.06 32.18 0.92 Allowed 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.9 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 58.44 46.78 92.62 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.239 -0.982 . . . . 0.0 111.739 -178.561 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 16' ' ' VAL . 41.8 t -146.07 106.51 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.656 0.265 . . . . 0.0 110.719 179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.739 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -111.18 143.95 41.12 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.073 178.734 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -116.09 77.81 1.13 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.086 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 13' ' ' GLY . 2.8 p -96.73 165.23 12.23 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.212 -178.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.414 ' O ' ' HG3' ' A' ' 11' ' ' LYS . 13.8 pttm 39.4 35.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.553 -1.203 . . . . 0.0 112.914 179.422 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 73.39 33.02 1.15 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.276 179.176 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -156.26 141.47 8.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.477 179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.719 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 5.8 m -91.36 137.68 32.18 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.442 0.639 . . . . 0.0 110.696 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 88.4 p -141.65 167.46 22.11 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.453 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.962 HG22 HG22 ' A' ' 7' ' ' VAL . 93.4 t -135.31 126.79 45.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.978 -179.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -72.37 -22.48 61.14 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.684 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.1 m95 68.26 -66.27 0.23 Allowed 'General case' 0 CA--C 1.507 -0.677 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.37 179.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.82 -28.7 39.99 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.448 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.448 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 1.4 mm-40 -75.65 -40.68 55.77 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.406 0.622 . . . . 0.0 109.337 178.015 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -70.55 -40.58 73.29 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.175 179.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.883 ' O ' HG23 ' A' ' 26' ' ' VAL . 19.8 t80 -60.73 -40.09 91.1 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.339 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.459 ' O ' ' ND1' ' A' ' 27' ' ' HIS . 78.7 p -69.44 -27.78 65.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.762 177.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.24 -51.81 12.41 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.175 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.711 ' O ' ' HG ' ' A' ' 29' ' ' LEU . . . -62.2 -42.44 99.72 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.452 179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.883 HG23 ' O ' ' A' ' 22' ' ' PHE . 58.1 t -63.6 -37.02 78.51 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 116.618 0.209 . . . . 0.0 111.512 -179.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.525 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 1.6 m-70 -61.4 -36.88 81.52 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -69.41 -49.7 52.75 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.023 178.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.711 ' HG ' ' O ' ' A' ' 25' ' ' GLY . 2.4 mt -71.55 -50.29 32.57 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 121.473 0.654 . . . . 0.0 111.634 -179.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 26' ' ' VAL . . . -70.01 -6.5 33.89 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 114.79 -1.096 . . . . 0.0 113.308 -177.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.525 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 31.0 t30 -80.76 -23.95 38.99 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.437 -0.505 . . . . 0.0 110.682 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -68.2 -65.88 2.52 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.184 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 164.7 -83.73 0.11 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.444 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -152.06 -42.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.696 0.284 . . . . 0.0 111.012 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.451 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -162.53 73.19 0.19 Allowed Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.536 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.451 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 91.9 m-85 -161.06 70.87 0.39 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.821 0.343 . . . . 0.0 110.542 179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 19.4 t90 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.845 179.958 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.626 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 5.5 ptpp? . . . . . 0 N--CA 1.487 1.415 0 CA-C-O 120.397 0.141 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.781 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.3 OUTLIER -80.39 139.16 36.65 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.542 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.425 ' HD2' HG12 ' A' ' 7' ' ' VAL . 28.7 m-85 -106.55 36.32 2.66 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.217 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 42.15 24.94 0.21 Allowed Glycine 0 C--N 1.338 0.655 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.78 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -146.82 36.61 0.95 Allowed 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.858 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 53.87 47.51 65.35 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.256 -0.974 . . . . 0.0 111.766 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 16' ' ' VAL . 53.2 t -142.2 106.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-O 121.077 0.465 . . . . 0.0 110.806 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.781 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -118.15 147.31 43.45 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.877 178.882 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.701 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 10.8 m -116.86 86.76 2.56 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.409 0.623 . . . . 0.0 110.03 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.87 ' O ' ' N ' ' A' ' 12' ' ' SER . 17.6 p -98.62 129.55 45.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.683 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 10.2 mttt 25.08 -54.44 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 178.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.87 ' N ' ' O ' ' A' ' 10' ' ' THR . 81.4 p -80.72 3.08 23.41 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.034 0.383 . . . . 0.0 112.034 -178.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . 115.93 -159.99 13.57 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.318 -0.944 . . . . 0.0 112.713 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.701 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 60.7 m -91.69 134.65 34.52 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.505 0.669 . . . . 0.0 110.961 179.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.9 m -138.6 172.12 13.35 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.648 -1.16 . . . . 0.0 109.983 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.942 HG22 HG22 ' A' ' 7' ' ' VAL . 88.9 t -133.65 128.47 54.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.918 0.389 . . . . 0.0 112.036 -179.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -71.77 -22.85 61.53 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 177.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.723 ' H ' HG12 ' A' ' 16' ' ' VAL . 93.9 m95 67.82 -59.73 0.41 Allowed 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.164 179.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.14 -26.76 64.04 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 118.94 -1.6 . . . . 0.0 110.485 178.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.432 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -76.43 -41.87 46.02 Favored 'General case' 0 CA--C 1.518 -0.272 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.116 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.42 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.4 -38.18 77.84 Favored 'General case' 0 CA--C 1.512 -0.491 0 CA-C-N 115.027 -0.988 . . . . 0.0 109.579 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.803 ' O ' HG23 ' A' ' 26' ' ' VAL . 22.0 t80 -60.23 -38.46 83.47 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.426 ' O ' ' CG ' ' A' ' 27' ' ' HIS . 2.9 m -69.52 -27.27 65.03 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.592 177.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -75.42 -52.44 10.73 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.06 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.45 -38.29 96.13 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.142 -0.935 . . . . 0.0 112.801 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.803 HG23 ' O ' ' A' ' 22' ' ' PHE . 90.8 t -66.05 -42.04 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.294 0 CA-C-N 117.19 0.495 . . . . 0.0 110.521 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.471 ' O ' ' CA ' ' A' ' 31' ' ' ASN . 0.9 OUTLIER -60.08 -43.54 95.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.674 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 4.8 tpm_? -74.77 -41.59 59.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.259 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.5 tp -72.27 -61.37 1.82 Allowed 'General case' 0 CA--C 1.519 -0.218 0 CA-C-O 121.433 0.635 . . . . 0.0 110.58 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.454 ' N ' ' O ' ' A' ' 26' ' ' VAL . . . -72.45 -54.31 9.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.443 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' CA ' ' O ' ' A' ' 27' ' ' HIS . 7.4 p30 45.24 32.85 1.04 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.651 179.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.58 -84.28 0.06 OUTLIER Glycine 0 C--N 1.331 0.304 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.588 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 149.58 100.45 0.22 Allowed Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.881 -0.675 . . . . 0.0 112.363 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.9 p30 45.33 76.95 0.08 Allowed 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.971 0.415 . . . . 0.0 110.946 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.93 -118.84 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.64 -179.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -163.31 -78.85 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.706 0.289 . . . . 0.0 110.787 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.232 -0.889 . . . . 0.0 110.689 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 8' ' ' HIS . 6.7 ptpt . . . . . 0 N--CA 1.484 1.249 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' TYR . . . . . 0.714 ' CE1' ' CD2' ' A' ' 8' ' ' HIS . 0.4 OUTLIER -78.92 139.59 38.25 Favored 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.469 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.466 ' HD2' HG12 ' A' ' 7' ' ' VAL . 35.6 m-85 -105.31 34.67 3.13 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 179.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 43.86 23.55 0.39 Allowed Glycine 0 C--N 1.338 0.692 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.893 -179.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -145.22 33.99 1.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.982 ' O ' HG13 ' A' ' 16' ' ' VAL . . . 55.92 45.83 85.46 Favored Glycine 0 C--O 1.224 -0.498 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.507 -178.144 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.744 HG22 HG22 ' A' ' 16' ' ' VAL . 54.0 t -139.55 102.58 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 O-C-N 122.824 -0.221 . . . . 0.0 110.768 -179.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.714 ' CD2' ' CE1' ' A' ' 2' ' ' TYR . 0.0 OUTLIER -110.26 135.76 50.52 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.356 179.088 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.749 ' HA ' ' HA ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -106.11 78.1 1.28 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.639 0.733 . . . . 0.0 109.912 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.484 ' O ' ' N ' ' A' ' 12' ' ' SER . 5.4 p -96.5 -166.59 1.44 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.61 -1.177 . . . . 0.0 111.701 -178.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 37.27 -85.09 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 114.962 -1.017 . . . . 0.0 112.574 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.484 ' N ' ' O ' ' A' ' 10' ' ' THR . 0.3 OUTLIER -149.3 21.31 0.95 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.47 -179.492 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 9' ' ' CYS . . . -172.68 -175.88 40.93 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.474 -0.87 . . . . 0.0 112.71 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.749 ' HA ' ' HA ' ' A' ' 9' ' ' CYS . 23.1 m -94.97 142.0 27.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.484 0.659 . . . . 0.0 111.584 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.0 m -137.74 161.07 37.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.084 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.982 HG13 ' O ' ' A' ' 6' ' ' GLY . 65.2 t -130.1 128.03 64.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 18' ' ' TRP . 4.4 m-20 -67.94 -28.72 67.71 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 177.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.613 ' H ' HG12 ' A' ' 16' ' ' VAL . 97.5 m95 74.86 -68.92 0.19 Allowed 'General case' 0 CA--C 1.512 -0.515 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.125 179.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.45 -29.68 24.37 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 118.972 -1.585 . . . . 0.0 110.487 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.425 ' CB ' ' OH ' ' A' ' 2' ' ' TYR . 0.6 OUTLIER -75.18 -44.86 44.25 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 178.036 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.405 ' HB2' ' HA3' ' A' ' 6' ' ' GLY . . . -69.33 -35.0 75.48 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.532 179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.886 ' O ' HG23 ' A' ' 26' ' ' VAL . 77.0 t80 -59.39 -37.75 78.79 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.667 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.28 -27.74 64.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.333 -0.848 . . . . 0.0 108.929 177.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -76.1 -51.77 11.54 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.154 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.88 -45.11 96.85 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.482 -0.865 . . . . 0.0 111.651 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.886 HG23 ' O ' ' A' ' 22' ' ' PHE . 70.3 t -57.41 -44.77 85.07 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.46 0 CA-C-N 117.285 0.543 . . . . 0.0 111.81 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.489 ' O ' ' HB2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -59.84 -44.43 94.09 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 120.154 -0.618 . . . . 0.0 109.689 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -70.8 -40.38 72.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.527 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 24.8 tp -76.32 -51.73 11.36 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -69.84 -21.17 63.38 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.489 ' HB2' ' O ' ' A' ' 27' ' ' HIS . 0.3 OUTLIER -80.67 -26.49 37.57 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.753 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -85.09 -89.82 0.86 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.096 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 153.43 56.81 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.293 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 61.4 m-20 53.74 95.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.641 0.258 . . . . 0.0 111.006 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.497 ' O ' ' CG ' ' A' ' 36' ' ' PHE . . . -172.54 111.42 0.39 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.974 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.497 ' CG ' ' O ' ' A' ' 35' ' ' GLY . 15.9 p90 50.67 173.56 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 121.112 0.482 . . . . 0.0 111.833 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 12.0 t-105 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.694 -179.418 . . . . . . . . 0 0 . 1 stop_ save_